var title_f41_25_42384="Non Hodgkins lymphoma Endosc";
var content_f41_25_42384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67755%7EGAST%2F72196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67755%7EGAST%2F72196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-Hodgkin's lymphoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 222px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopic view of a friable, indurated mucosa with scattered areas of ulceration suggestive of inflammatory bowel disease. Histology was consistent with a non-Hodgkin's lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Non-Hodgkin lymphoma of rectum on endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the rectum in a 95-year-old patient who presented with weight loss and anemia. The biopsy revealed non Hodgkins lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alfonso Sandoval, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42384=[""].join("\n");
var outline_f41_25_42384=null;
var title_f41_25_42385="Fungal nail infections Hyper-IgE";
var content_f41_25_42385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Destructive fungal nail infections in a patient with hyperimmunoglobulin E syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42385=[""].join("\n");
var outline_f41_25_42385=null;
var title_f41_25_42386="Anatomy wrist radial";
var content_f41_25_42386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Anatomy of the radial aspect of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 585px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42386=[""].join("\n");
var outline_f41_25_42386=null;
var title_f41_25_42387="WHO weight for length girls 0 to 24 months";
var content_f41_25_42387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Weight-for-length percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 508px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42387=[""].join("\n");
var outline_f41_25_42387=null;
var title_f41_25_42388="Compartments of neck";
var content_f41_25_42388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Anatomical regions of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42388=[""].join("\n");
var outline_f41_25_42388=null;
var title_f41_25_42389="Atypical and malignant meningiomas";
var content_f41_25_42389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atypical and malignant meningiomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     Helen A Shih, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     John K Park, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     Peter McLaren Black, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42389/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/25/42389/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H444764622\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas account for approximately one-third of primary central nervous system tumors (",
"    <a class=\"graphic graphic_table graphicRef81566 \" href=\"mobipreview.htm?6/44/6862\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72275 \" href=\"mobipreview.htm?28/44/29391\">",
"     figure 1",
"    </a>",
"    ). Most meningiomas are benign (WHO grade I), although up to one-third of such tumors are classified as atypical (World Health Organization [WHO] grade II) or malignant (WHO grade III). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=see_link&amp;anchor=H627075368#H627075368\">",
"     \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with meningioma requires a balance between definitive treatment of the tumor and avoidance of neurologic damage from the treatment. Patient-specific factors (eg, presence or absence of symptoms, age, comorbidity), the location of the meningioma in relation to critical brain structures and regions, and the histopathologic characteristics (WHO grade) of the meningioma all are important factors in determining the optimal treatment.",
"   </p>",
"   <p>",
"    WHO grade II and grade III meningiomas will be reviewed here. Other topics on meningioma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiology and risk factors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=see_link\">",
"       \"Meningioma: Epidemiology, risk factors, and pathology\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Clinical presentation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=see_link\">",
"       \"Meningioma: Clinical presentation and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment benign (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44616?source=see_link\">",
"       \"Treatment of benign (WHO grade I) meningioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systemic treatment for recurrent meningioma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4133?source=see_link\">",
"       \"Systemic treatment of recurrent meningioma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444764629\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas are classified according to the World Health Organization (WHO) schema, which is based upon strict morphologic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/1\">",
"     1",
"    </a>",
"    ]. The current version of the WHO classification system was promulgated in 2007. This system divides meningiomas into three groups, based upon morphologic criteria, and has been shown to correlate with prognosis and thus has important implications for patient management (",
"    <a class=\"graphic graphic_table graphicRef72593 \" href=\"mobipreview.htm?20/19/20796\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Meningiomas with an increased risk of recurrence are divided into WHO grade II and grade III tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      WHO grade II meningiomas have increased mitotic activity (&gt;4 mitoses per 10 high powered fields) and three or more of the following features: increased cellularity, small cells with a high nuclear:cytoplasmic ratio, prominent nucleoli, uninterrupted patternless or sheet-like growth, or foci of spontaneous or geographic necrosis (",
"      <a class=\"graphic graphic_picture graphicRef60534 \" href=\"mobipreview.htm?39/26/40355\">",
"       picture 1",
"      </a>",
"      ). Atypical, clear cell, and chordoid meningiomas are classified as WHO grade II. Case series using the 2007 WHO criteria estimate that 20 to 35 percent of meningiomas are classified as WHO grade II.",
"     </li>",
"     <li>",
"      WHO grade III meningiomas have &ge;20 mitoses per high powered field",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      malignant characteristics resembling carcinoma, sarcoma, or melanoma (",
"      <a class=\"graphic graphic_picture graphicRef60534 \" href=\"mobipreview.htm?39/26/40355\">",
"       picture 1",
"      </a>",
"      ). Papillary, rhabdoid, and anaplastic meningiomas are classified as WHO grade III. WHO grade III meningiomas constitute about 1 to 3 percent of all cases of meningioma.",
"      <br/>",
"      <br/>",
"      Although WHO grade III meningiomas are considered malignant, distant metastasis is rare and the primary issue is local recurrence, which can necessitate addition treatment and ultimately can cause death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At one time, hemangiopericytomas were classified as a variant of WHO grade III meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/3\">",
"     3",
"    </a>",
"    ]. Although there are histologic and immunochemical similarities, hemangiopericytomas are now considered a distinct tumor type, with a somewhat better prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35946?source=see_link&amp;anchor=H31#H31\">",
"     \"Uncommon brain tumors\", section on 'Hemangiopericytomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major difference between the 2007 and 2000 WHO grading versions is that brain invasion in an otherwise grade I meningioma is a criterion for classification as grade II. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=see_link&amp;anchor=H627075368#H627075368\">",
"     \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444764636\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of meningioma is generally suspected on the basis of characteristic imaging findings and is then confirmed by histopathology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=see_link&amp;anchor=H22#H22\">",
"     \"Meningioma: Clinical presentation and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differentiating an atypical or malignant meningioma from a benign meningioma purely on the basis of neuroimaging is difficult. Features that may suggest the presence of a high-grade meningioma rather than a benign meningioma include the presence of intratumoral cystic change, hyperostosis of the adjacent skull, bone destruction, extension of tumor through the skull base, arterial encasement, and peritumoral brain edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. PET scanning has shown more intense uptake in some but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, none of these neuroimaging findings is sufficiently specific to be clinically useful. Furthermore, the initial therapeutic approach for all meningiomas is surgical resection if feasible, depending upon the size and location of the lesion, as well as the patient&rsquo;s overall condition and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444764643\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to patients with a presumed meningioma is complete surgical resection if feasible, depending upon the location of the lesion and the patient&rsquo;s overall condition. For patients with an atypical or malignant meningioma, adjuvant radiation therapy (RT) is now considered a standard component of initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H537373850\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete surgical resection is preferred when a meningioma is in an accessible location, since complete resection of the tumor and its dural attachment can be curative. Multiple advances in neurosurgery, including microsurgery, improved preoperative imaging, and intraoperative image-guided approaches, have extended the neurosurgeon's ability to resect lesions that were previously considered only partially resectable or unresectable, while minimizing damage to normal brain. The goals of surgery, the classification of the extent of surgical resection, surgical morbidity, and the perioperative medical management for all patients with meningioma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44616?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of benign (WHO grade I) meningioma\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although surgery has an important role in the management of WHO grade II and III meningiomas, resection alone is generally considered inadequate because of the high rate of local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Older observational studies suggested that the addition of adjuvant radiation therapy (RT) decreased the rate of local recurrence and improved survival and that the benefit of RT was dependent upon the dose of radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H537373725\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no results from prospective, randomized trials in patients with atypical or malignant meningiomas, RT is often used after presumed complete resection of atypical or malignant meningiomas because of the relatively high rate of local recurrence. Newer RT techniques that have been used in small series include stereotactic radiosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], hypofractionated stereotactic RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], and heavy particle irradiation (proton beam, carbon ion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. None of these approaches has been shown to be superior to contemporary conformal techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H537373553\">",
"    <span class=\"h2\">",
"     Results of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data come from retrospective case series, and the interpretation of older series is limited by the rarity of atypical and malignant meningiomas. Furthermore, these series generally are heterogeneous, having used a variety of pathologic criteria to define intermediate and high-risk meningiomas, as well as containing mixtures of different treatment strategies (differing anatomic locations, variable extent of surgical resection, immediate adjuvant RT versus salvage RT for recurrence after surgery).",
"   </p>",
"   <p>",
"    Several contemporary observational series illustrate the natural history of these tumors, the impact of histopathology on prognosis, and the potential importance of a combined approach using surgery and postoperative adjuvant RT in patients with atypical or high-grade meningiomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective, single-institution series analyzed outcomes in 108 patients who underwent a gross total resection (Simpson grade I) for an atypical (WHO Grade II) meningioma between 1993 and 2004 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/15\">",
"       15",
"      </a>",
"      ]. Patients were classified as have a grade II meningioma based upon the WHO",
"      <span class=\"nowrap\">",
"       2000/2007",
"      </span>",
"      criteria.",
"      <br/>",
"      <br/>",
"      In this series, 100 patients were treated with surgery alone, while eight patients received immediate adjuvant RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/15\">",
"       15",
"      </a>",
"      ]. Overall, 30 patients recurred after apparent gross total resection without adjuvant RT; none of the eight patients who received adjuvant RT (59 to 61 Gy) recurred. For the entire cohort, the actuarial recurrence rates at 1, 5, and 10 years were 7, 41, and 48 percent. All patients with a recurrence were subsequently treated with RT, and 22 of 30 (73 percent) had one or more additional surgeries. Disease-specific survival after first recurrence was 86 and 69 percent at 5 and 10 years, respectively.",
"     </li>",
"     <li>",
"      Another contemporary series also suggested the importance of both gross total resection and adjuvant RT. The treatment of 45 patients with histologically confirmed WHO grade II meningiomas included surgery alone in 21 patients and surgery plus external beam RT (range 54 to 61 Gy, median 61 Gy) in 24 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/16\">",
"       16",
"      </a>",
"      ]. At a median follow-up of over three years, the five-year progression-free survival rates with gross total resection, gross total resection plus RT, lesser resection alone, and lesser resection plus RT were 46, 78, 0, and 56 percent, respectively. On multivariate analysis, both gross total resection and postoperative RT were associated with a better outcome.",
"     </li>",
"     <li>",
"      A report from the Rare Cancer Network analyzed outcome and prognostic factors in a series of 119 patients with meningiomas seen at ten centers over a 35-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients were classified as atypical or malignant in 69 and 31 percent of cases, respectively. All patients were treated with RT, either in conjunction with their initial surgery or at recurrence (79 and 21 percent of cases, respectively). Radiation doses ranged from 40 to 66 Gy (mean 55 Gy). The 5 and 10-year overall survival rates were 65 and 51 percent, respectively.",
"     </li>",
"     <li>",
"      The particularly poor prognosis in patients with malignant meningioma was illustrated by a series of 13 cases from a single institution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/17\">",
"       17",
"      </a>",
"      ]. All patients were classified as WHO grade III; in six cases, patients had previously been treated for benign meningiomas. All patients underwent surgical resection, but only three received adjuvant RT as part of their initial therapy. Surgery, stereotactic radiosurgery,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT were used to treat recurrences.",
"      <br/>",
"      <br/>",
"      One patient died postoperatively, and 11 of the remaining 12 (92 percent) recurred (time to recurrence ranged from 0.4 to 2.8 years). The five and eight-year actuarial survival rates were 47 and 12 percent.",
"     </li>",
"     <li>",
"      Somewhat better results were reported in series of 63 patients with malignant (WHO grade III) meningiomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/18\">",
"       18",
"      </a>",
"      ]. All patients were managed initially with surgery and RT. Actuarial recurrence-free survival rates at 2, 5, and 10 years after initial therapy were 80, 57, and 40 percent, respectively, and overall survival rates were 82, 61, and 40 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444764650\">",
"    <span class=\"h2\">",
"     Ongoing protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prospective, phase II cooperative group protocols are studying the role of RT in the management of patients with WHO grade II or III meningioma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RTOG 0539 (NCT00895622) &ndash; In a study being conducted by the Radiation Therapy Oncology Group, patients with low-risk meningiomas are being managed with clinical observation following initial surgery, while those with intermediate or high-risk disease are receiving six weeks of RT using either three-dimensional conformal RT or intensity-modulated RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/19\">",
"       19",
"      </a>",
"      ]. A dose of 54 Gy is used for newly diagnosed patients following a gross total resection, and a dose of 60 Gy is used for those with newly diagnosed meningioma and a subtotal resection as well as those with recurrent, atypical meningioma.",
"     </li>",
"     <li>",
"      EORTC 22042 (NCT00626730) &ndash; In a phase II study run by the European Organization for Research and Treatment of Cancer, patients with atypical or malignant meningioma are being treated with adjuvant RT following surgical resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/19\">",
"       19",
"      </a>",
"      ]. A dose of 54 Gy is used for newly diagnosed patients with atypical meningioma following a gross total resection, and a dose of 60 Gy is used for those with newly diagnosed anaplastic meningioma with any extent of resection and with atypical meningiomas that are subtotally resected or recurrent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No results from these studies are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444764685\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most recurrences of meningioma are local or adjacent to a radiation treatment field. Metastases of cranial meningiomas to the spinal cord due to spreading through the cerebrospinal fluid are rare and are more frequently associated with atypical or malignant meningiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There are only isolated case reports of metastases outside the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42389/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who recur locally after their initial treatment, additional surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT (SRS, SRT, combined proton and photon RT) can sometimes provide effective therapy, and occasionally permit long-term overall and recurrence-free survival. The principles underlying the use of surgery or radiation are similar to those for patients presenting de novo, but appropriate management requires a consideration of the effects of prior surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44616?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of benign (WHO grade I) meningioma\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44616?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of benign (WHO grade I) meningioma\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic therapy for recurrent disease is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4133?source=see_link\">",
"     \"Systemic treatment of recurrent meningioma\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444764692\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical (WHO grade II) and malignant (WHO grade III) meningiomas are distinguished from benign (WHO grade I) meningiomas based upon specific histopathologic criteria. This distinction is important because these tumors are associated with a significantly increased rate of local recurrence and subsequent morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H444764629\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H537373553\">",
"       'Results of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete surgical resection is the preferred initial approach when a meningioma is in an accessible location, since complete resection of the tumor and its dural attachment can be curative. (See",
"      <a class=\"local\" href=\"#H537373850\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are no randomized trials, adjuvant radiation therapy is considered a standard component of initial therapy because of the high rate of local recurrence. Radiation therapy is also used for patients in whom a complete initial resection is not possible. (See",
"      <a class=\"local\" href=\"#H537373725\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Perry, A, Louis, DN, Scheithauer, BW, et, al. Meningiomas. In: WHO Classification of Tumours of the Central Nervous System, Louis, DN, Ohgaki, H, Wiestler, OD (Eds), IARC Press, Lyon 2007. p.164.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/2\">",
"      Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol 2010; 99:433.",
"     </a>",
"    </li>",
"    <li>",
"     Giannini, C, Rushing, EJ, Hainfellner, JA. Haemangiopericytoma. In: WHO Classification of Tumours of the Central Nervous System, Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK (Eds), IARC Press, Lyon 2007. p.178.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/4\">",
"      Hsu CC, Pai CY, Kao HW, et al. Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci 2010; 17:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/5\">",
"      Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 2010; 99:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/6\">",
"      Milosevic MF, Frost PJ, Laperriere NJ, et al. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 1996; 34:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/7\">",
"      Dziuk TW, Woo S, Butler EB, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 1998; 37:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/8\">",
"      Harris AE, Lee JY, Omalu B, et al. The effect of radiosurgery during management of aggressive meningiomas. Surg Neurol 2003; 60:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/9\">",
"      Huffmann BC, Reinacher PC, Gilsbach JM. Gamma knife surgery for atypical meningiomas. J Neurosurg 2005; 102 Suppl:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/10\">",
"      Kano H, Takahashi JA, Katsuki T, et al. Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol 2007; 84:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/11\">",
"      Girvigian MR, Chen JC, Rahimian J, et al. Comparison of early complications for patients with convexity and parasagittal meningiomas treated with either stereotactic radiosurgery or fractionated stereotactic radiotherapy. Neurosurgery 2008; 62:A19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/12\">",
"      Lominska CE, Unger K, Jean WC, et al. Multisession stereotactic radiosurgery for meningioma results in low rates of post-treatment edema. Int J Radiat Oncol Biol Phys 2009. (Available online at file://astro2009.abstractsnet.com/pdfs/2135.pdfaccessed June 19, 2012).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/13\">",
"      Boskos C, Feuvret L, Noel G, et al. Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys 2009; 75:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/14\">",
"      Combs SE, Hartmann C, Nikoghosyan A, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiother Oncol 2010; 95:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/15\">",
"      Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009; 64:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/16\">",
"      Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2008; 71:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/17\">",
"      Rosenberg LA, Prayson RA, Lee J, et al. Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys 2009; 74:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/18\">",
"      Sughrue ME, Sanai N, Shangari G, et al. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg 2010; 113:202.",
"     </a>",
"    </li>",
"    <li>",
"     ClinicalTrials.gov file://www.clinicaltrials.gov/ (Accessed on October 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/20\">",
"      Chuang HC, Lee HC, Cho DY. Intracranial malignant meningioma with multiple spinal metastases--a case report and literature review: case report. Spine (Phila Pa 1976) 2006; 31:E1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/21\">",
"      Chamberlain MC, Glantz MJ. Cerebrospinal fluid-disseminated meningioma. Cancer 2005; 103:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/22\">",
"      Slavin ML. Metastatic malignant meningioma. J Clin Neuroophthalmol 1989; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42389/abstract/23\">",
"      Figueroa BE, Quint DJ, McKeever PE, Chandler WF. Extracranial metastatic meningioma. Br J Radiol 1999; 72:513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15692 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42389=[""].join("\n");
var outline_f41_25_42389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H444764692\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444764622\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444764629\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444764636\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444764643\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H537373850\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H537373725\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H537373553\">",
"      Results of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444764650\">",
"      Ongoing protocols",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444764685\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444764692\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15692|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/44/29391\" title=\"figure 1\">",
"      Incidence rates of primary brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15692|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/26/40355\" title=\"picture 1\">",
"      Histologic appearance of meningioma grades I-III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15692|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/44/6862\" title=\"table 1\">",
"      CBTRUS incidence of primary CNS tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/19/20796\" title=\"table 2\">",
"      Meningioma subtypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4133?source=related_link\">",
"      Systemic treatment of recurrent meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_25_42390="Methamphetamine: Drug information";
var content_f41_25_42390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methamphetamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/1/12309?source=see_link\">",
"    see \"Methamphetamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/6/29798?source=see_link\">",
"    see \"Methamphetamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Desoxyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desoxyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anorexiant;",
"     </li>",
"     <li>",
"      Central Nervous System Stimulant;",
"     </li>",
"     <li>",
"      Sympathomimetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Exogenous obesity:",
"     </b>",
"     Oral: 5 mg given 30 minutes before each meal; treatment duration should not exceed a few weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/6/29798?source=see_link\">",
"      see \"Methamphetamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ADHD:",
"     </b>",
"     Oral: Children &ge;6 years: Initial: 5 mg 1-2 times daily; may increase by 5 mg increments at weekly intervals until optimum response is achieved; usual effective dose range: 20-25 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Exogenous obesity:",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desoxyn&reg;: 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F194098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088582.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088582.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14633138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Late evening doses should be avoided due to potential for insomnia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD); short-term (few weeks) adjunct to caloric restriction in exogenous obesity",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pharmacotherapy for weight loss is recommended only for obese patients with a body mass index &ge;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , or &ge;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     in the presence of other risk factors such as hypertension, diabetes, and/or dyslipidemia or a high waist circumference; therapy should be used in conjunction with a comprehensive weight management program.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F194093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Narcolepsy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Desoxyn&reg; may be confused with digoxin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, dysphoria, euphoria, exacerbation of motor and phonic tics and Tourette's syndrome, headache, insomnia, overstimulation, psychosis, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Change in libido",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, unpleasant taste, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Suppression of growth in children, tolerance and withdrawal with prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methamphetamine, any component of the formulation, or idiosyncrasy to amphetamines or other sympathomimetic amines; patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma, agitated states; patients with a history of drug abuse; use during or within 14 days following MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: CNS stimulant use has been associated with serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke and MI in adults). These products should be avoided in the patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Patients who develop angina, unexplained syncope, or other symptoms of cardiac disease during therapy should be evaluated immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential:",
"     <b>",
"      [U.S. Boxed Warning]: Potential for drug dependency and abuse exists.",
"     </b>",
"     Misuse has resulted in death including fatal cardiorespiratory arrest. Use is contraindicated in patients with history of ethanol or drug abuse. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; antidiabetic agent requirements may be altered with anorexigens and concomitant dietary restrictions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions (heart failure, recent MI, ventricular arrhythmia) that might be exacerbated by increases in blood pressure or heart rate. Use is contraindicated in patients with moderate-to-severe hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use with caution in patients with pre-existing psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new onset psychosis or mania may occur with stimulant use; observe for symptoms of aggression and/or hostility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity. Discontinue use if seizures occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in this age group due to the risk for causing dependence, hypertension, angina, and myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use of stimulants has been associated with suppression of growth; monitor growth rate during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders. Aggression and hostility has been reported with use of medications for ADHD treatment; no evidence suggests that stimulants cause aggressive behavior but patient should be monitored for the onset or exacerbation of these behaviors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Abrupt discontinuation following high doses or for prolonged periods may result in symptoms for withdrawal. Discontinue if satisfactory weight loss has not occurred within the first 4 weeks of treatment, or if tolerance develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inappropriate use: Therapy is not appropriate for the treatment of fatigue in normal patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight reduction: Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Use in weight reduction programs only when alternative therapy has been ineffective.  Avoid prolonged treatment durations due to potential for drug dependence.",
"     </b>",
"     Tolerance to the anorectic effect generally develops with a few weeks; when tolerance develops, discontinue therapy rather than increase the dose in an attempt to increase the effect.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F194081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may cause CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Amphetamine serum levels may be altered if taken with acidic food, juices, or vitamin C. Management: Avoid caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Ephedra may cause hypertension or arrhythmias. Management: Avoid ephedra.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2890217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse effects have been observed in animal reproduction studies. Methamphetamine and amphetamine were detected in newborn tissues following intermittent maternal use of Desoxyn&reg; during pregnancy (Garriott, 1973). The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F194088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14633128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Amphetamines are excreted into breast milk and use may decrease milk production. Increased irritability, agitation, and crying have been reported in nursing infants (ACOG, 2011). The manufacturer recommends that mothers taking methamphetamine refrain from nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F194075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most effective when combined with a low calorie diet and behavior modification counseling.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Desoxyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $553.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methamphetamine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $432.31",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F194064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, respiratory rate, blood pressure, CNS activity, body weight (BMI); growth rate in children",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008). Monitor for aggression and hostility.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4152535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adult classification of weight by BMI (kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Underweight: &lt;18.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Normal: 18.5-24.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Overweight: 25-29.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class I: 30-34.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class II: 35-39.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extreme obesity (class III): &ge;40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Waist circumference: In adults with a BMI of 25-34.9 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , high-risk waist circumference is defined as:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Men &gt;102 cm (&gt;40 in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Women &gt;88 cm (&gt;35 in)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F194076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cidrin (CL);",
"     </li>",
"     <li>",
"      Desoxyn (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A sympathomimetic amine related to ephedrine and amphetamine with CNS stimulant activity; causes release of catecholamines (primarily dopamine and other catecholamines) from their storage sites in the presynaptic nerve terminals. Inhibits reuptake and metabolism of catecholamines through inhibition of monoamine transporters and oxidase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Predominately hepatic via aromatic hydroxylation, N-dealkylation and deamination; forms &ge;7 metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine primarily (dependent on urine pH; alkaline urine increases the half-life); 62% of dose eliminated within first 24 hours as ~33% unchanged drug with remainder as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists (ACOG) Committee Opinion: No. 479, &ldquo;Methamphetamine Abuse in Women of Reproductive Age,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):751-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/21343793/pubmed\" id=\"21343793\" target=\"_blank\">",
"        21343793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults,&rdquo;",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 1998, 68(4):899-917.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/9771869/pubmed\" id=\"9771869\" target=\"_blank\">",
"        9771869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garriott JC and Spruill FG, \"Detection of Methamphetamine in a Newborn Infant,\"",
"      <i>",
"       J Forensic Sci",
"      </i>",
"      , 1973, 18(4):434-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/4784309/pubmed\" id=\"4784309\" target=\"_blank\">",
"        4784309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert RB, Peng PI,and Wong D, &ldquo;A Labetalol Metabolite With Analytical Characteristics Resembling Amphetamines,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(2):84-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/7769792/pubmed\" id=\"7769792\" target=\"_blank\">",
"        7769792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golub M, Costa L, Crofton K, et al, \"NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,\"",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2005, 74(6):471-584.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/16167346/pubmed\" id=\"16167346\" target=\"_blank\">",
"        16167346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gospe SM Jr, &ldquo;Transient Cortical Blindness in an Infant Exposed to Methamphetamine,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 26(3):380-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/7661433/pubmed\" id=\"7661433\" target=\"_blank\">",
"        7661433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaGasse LL, Derauf C, Smith LM, et al, \"Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(4):681-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/22430455/pubmed\" id=\"22430455\" target=\"_blank\">",
"        22430455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mendelson J, Jones RT, Upton R, et al, &ldquo;Methamphetamine and Ethanol Interactions in Humans,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(5):559-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/7768079/pubmed\" id=\"7768079\" target=\"_blank\">",
"        7768079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nestor TA, Tamamoto WI, Kam TH, et al, &ldquo;Acute Pulmonary Oedema Caused by Crystalline Methamphetamine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1989, 2(8674):1277-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richards CF, Clark RF, Holbrook T, et al, &ldquo;The Effect of Cocaine and Amphetamines on Vital Signs in Trauma Patients,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1995, 13(1):59-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/7782627/pubmed\" id=\"7782627\" target=\"_blank\">",
"        7782627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rothrock JF, Rubenstein R, and Lyden PD, &ldquo;Ischemic Stroke Associated With Methamphetamine Inhalation,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1988, 38(4):589-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/3352918/pubmed\" id=\"3352918\" target=\"_blank\">",
"        3352918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snow V, Barry P, Fitterman N, et al, &ldquo;Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 142(7):525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/15809464/pubmed\" id=\"15809464\" target=\"_blank\">",
"        15809464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sperling LS and Horowitz JL, &ldquo;Methamphetamine-Induced Choreoathetosis and Rhabdomyolysis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 121(12):986.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/7978734/pubmed\" id=\"7978734\" target=\"_blank\">",
"        7978734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;U.S. Preventative Services Task Force. Screening for Obesity in Adults: Recommendations and Rationale,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 139(11):933-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/14644897/pubmed\" id=\"14644897\" target=\"_blank\">",
"        14644897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/25/42390/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westfall TC, Westfall DP, &ldquo;Adrenergic Agonists and Antagonists,&rdquo;",
"      <i>",
"       Goodman and Gilman's The Pharmacological Basis of Therapeutics",
"      </i>",
"      , 11th ed, Brunton LL, ed, New York, NY: McGraw-Hill, 2006, 257-8.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9624 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42390=[""].join("\n");
var outline_f41_25_42390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709038\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194083\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194084\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194096\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194087\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194091\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062599\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194052\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194098\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874887\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14633138\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194068\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194093\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194104\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194094\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194056\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194092\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194061\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194081\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194062\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2890217\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194088\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14633128\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194075\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989407\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194064\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152535\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194076\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194055\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194071\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/1/12309?source=related_link\">",
"      Methamphetamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/6/29798?source=related_link\">",
"      Methamphetamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_25_42391="Adjuvant chemotherapy for malignant gliomas";
var content_f41_25_42391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant chemotherapy for malignant gliomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42391/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42391/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42391/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42391/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42391/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42391/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42391/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/25/42391/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13374802\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant gliomas are rapidly progressive brain tumors that are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) and glioblastoma (GBM) based upon their histopathologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=see_link&amp;anchor=H7347120#H7347120\">",
"     \"Classification of gliomas\", section on 'Histopathologic and molecular classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignant gliomas are best managed with a combined modality approach, incorporating adjuvant postoperative radiation therapy (RT) and adjuvant chemotherapy following initial surgery. Postoperative chemotherapy is discussed in this topic.",
"   </p>",
"   <p>",
"    Other topics that are covered separately include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with suspected brain tumors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Initial surgical management of malignant gliomas (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Postoperative RT (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Management of recurrent malignant gliomas (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link\">",
"       \"Management of recurrent malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Management of anaplastic oligodendroglial tumors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11655?source=see_link\">",
"       \"Treatment of oligodendroglial tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Experimental approaches to the treatment of malignant glioma (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=see_link\">",
"       \"Experimental treatment approaches for malignant gliomas\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGICAL RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A histologic diagnosis is required for optimal treatment of patients with brain tumors. This can be accomplished either at the time of surgical resection or with a stereotactic biopsy. Biopsy alone is used in situations where the lesion is not amenable to resection, a meaningful amount of tumor tissue cannot be removed, or the patient's overall clinical condition will not permit surgery.",
"   </p>",
"   <p>",
"    For patients with a newly-diagnosed malignant glioma, maximal surgical resection consistent with preservation of neurologic function is preferred. Although gross total resection is preferred whenever possible, subtotal resection or stereotactic biopsy may be required depending upon the location and extent of the tumor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link\">",
"     \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ADJUVANT RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even patients who undergo a gross total resection of their malignant glioma have a high recurrence rate. Adjuvant RT has been shown to improve local control and survival after resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"     \"Adjuvant radiation therapy for malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GLIOBLASTOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survival benefit with chemotherapy for patients with glioblastoma was initially demonstrated using the nitrosourea",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , and the nitrosoureas, either alone or in combination regimens, became the standard of care. Subsequent trials have established the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    as the current standard for adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    , an oral alkylating agent, is the preferred agent for concurrent chemoradiotherapy in patients with malignant glioblastomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of adjuvant treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    was demonstrated in a phase III trial in which 573 newly diagnosed patients with GBM were randomly assigned to postoperative involved-field RT (60 Gy in daily 30 fractions) versus the same RT plus concomitant temozolomide (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily up to 49 days) followed by up to six cycles of adjuvant temozolomide (150 to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days, every 28 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a median follow-up of over five years, the key results of this trial included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      plus RT was associated with a statistically significant prolongation of overall survival (27 versus 11 percent and 10 versus 2 percent at one and five years, respectively, hazard ratio [HR] for death 0.63, 95% CI 0.53-0.75). The outcome was particularly good in some subsets, such as those less than 50 years old, in whom the five-year survival was 17 percent with combination therapy.",
"     </li>",
"     <li>",
"      Methylation of the promoter for methyl guanine methyl transferase (MGMT) was a major prognostic factor for improved survival and was predictive of benefit from chemotherapy. For those with MGMT methylation, the two-year survival rates were 49 and 24 percent with combination therapy and with RT alone, respectively, while for those without MGMT methylation, the two-year survival rates were 15 and 2 percent, respectively. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'MGMT expression'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      This improvement in survival was achieved without a negative effect on health-related quality of life.",
"     </li>",
"     <li>",
"      Benefits from adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      were observed in all patient subsets, including those over 60 years and those with other poor prognostic factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were seen in a second, smaller phase III trial in patients with GBM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients being treated with daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    during radiation should receive pneumocystis pneumonia prophylaxis until recovery of leukopenia (",
"    <a class=\"graphic graphic_table graphicRef79988 \" href=\"mobipreview.htm?23/15/23804\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other schedules of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    have not been more effective. The phase III RTOG 0525 trial compared the standard schedule (150 to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days, every 28 days) with a dose dense schedule (75 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 21 repeated every four weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/7\">",
"     7",
"    </a>",
"    ]. Results presented at the 2011 American Society of Clinical Oncology (ASCO) meeting found no statistically significant difference in either overall or progression-free survival. The RTOG 0525 trial did confirm the importance of MGMT methylation as a prognostic marker, but there were no differences in survival with the two treatment regimens based upon MGMT status.",
"   </p>",
"   <p>",
"    There are no randomized trials that have compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    with a nitrosourea-based combination regimen when given concurrently with RT followed by adjuvant therapy. However, temozolomide was compared with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    (CCNU), plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (PCV) regimen in a phase III trial in 447 patients with malignant glioma at first recurrence following initial treatment with RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients assigned to temozolomide were randomly assigned to one of two dosing schedules (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for five days or 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for 21 days, each repeated every four weeks for nine months).",
"   </p>",
"   <p>",
"    There was no statistically significant difference in progression-free survival or in overall survival when patients treated with PCV were compared with those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . When the two temozolomide regimens were compared, those treated with the five-day regimen every four weeks had a significantly longer median progression-free and overall survival compared with the 21-day regimen (5.0 versus 4.2 months, and 8.5 versus 6.6 months, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nitrosoureas",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Systemic nitrosoureas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brain Tumor Study Group conducted multiple randomized trials evaluating the addition of adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    (alone or in combination with other agents) to postoperative RT. Although results varied between trials, there appeared to be a significant survival benefit from adding carmustine-based chemotherapy to adjuvant RT.",
"   </p>",
"   <p>",
"    The magnitude of the survival benefit was assessed in a meta-analysis that included individual patient data from 3004 patients enrolled in 12 randomized controlled trials comparing RT alone or with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/9\">",
"     9",
"    </a>",
"    ]. Chemotherapy was associated with a 15 percent decrease in the risk of death (hazard ratio [HR] 0.85, 95% CI 0.78 to 0.91), which translated to a 6 percent absolute increase in one-year survival (from 40 to 46 percent) and a two-month improvement in median survival.",
"   </p>",
"   <p>",
"    Multiple clinical trials compared single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    with various nitrosourea-based combinations. A meta-analysis of nine randomized trials involving over 2100 patients failed to demonstrate any benefit from combination chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/10\">",
"     10",
"    </a>",
"    ]. Despite these negative results, the PCV regimen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , [(",
"    <a class=\"graphic graphic_table graphicRef57806 \" href=\"mobipreview.htm?2/45/2780\">",
"     table 2",
"    </a>",
"    )]) was widely used prior to the development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Another nitrosourea, nimustine, was evaluated in a European phase III trial, in combination with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/11\">",
"     11",
"    </a>",
"    ]. In this trial of 362 patients with glioblastoma, the median survival was similar to that seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (16 and 17 months for nimustine plus teniposide and nimustine plus cytarabine, respectively). These nimustine combinations are limited by nitrosourea toxicities and the need for parenteral administration. These regimens have not been directly compared to temozolomide in a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Carmustine polymer",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     Carmustine",
"    </a>",
"    polymer wafers (Gliadel), which consist of carmustine embedded in a biodegradable matrix, function as a slow-release carrier system for local drug delivery. These wafers were originally approved as an adjunct to surgery for patients with recurrent GBM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link\">",
"     \"Management of recurrent malignant gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    wafers was subsequently extended to include its use as an adjunct to surgery and RT for patients with newly-diagnosed malignant glioma. In a phase III trial 240 newly-diagnosed adults undergoing resection of a malignant glioma were randomly assigned to placement of up to eight carmustine wafers or a placebo, followed by standard RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    polymer had a statistically significant increase in median survival (13.9 versus 11.6 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/12\">",
"     12",
"    </a>",
"    ]. When the analysis was restricted to patients with GBM, the difference in survival was not statistically significant. Toxicities with carmustine polymer were similar except for an increase in the incidence of cerebrospinal fluid (CSF) leak and intracranial hypertension compared to placebo (5 versus 1 percent and 9 versus 2 percent, respectively).",
"   </p>",
"   <p>",
"    There are no randomized trials assessing the effect of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    polymer wafers to RT plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . At least one retrospective comparison of RT plus temozolomide with or without carmustine polymer wafers failed to demonstrate any improvement in progression-free or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjuvant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    wafers has been associated with potentially fatal cerebral edema, which may be either acute or delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/14\">",
"     14",
"    </a>",
"    ]. While the early onset of cerebral edema may represent an early toxic effect of treatment, delayed onset may be a reaction to tumor necrosis. Aggressive medical management of symptoms of cerebral edema is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a monoclonal antibody that binds vascular endothelial growth factor (VEGF), which plays a critical role in the development of the abnormal vasculature observed in malignant gliomas and other tumors. In phase II studies in previously treated patients, bevacizumab reduced requirements for steroids and was associated with imaging evidence of tumor response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is being evaluated as a component of the initial combined modality approach in patients with newly diagnosed GBM. In a multicenter phase II study, 70 patients with newly diagnosed GBM were treated with bevacizumab (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) in combination with a standard regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    plus RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/15\">",
"     15",
"    </a>",
"    ]. The median overall and progression-free survival was 19.6 and 13.6 months, respectively. The side effect profile was consistent with that seen with bevacizumab in other clinical settings.",
"   </p>",
"   <p>",
"    Two phase III clinical trials are assessing the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in conjunction with RT plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    (NCT00884741 and NCT00943826) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360536\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant chemotherapy in elderly patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15029?source=see_link\">",
"     \"Management of malignant gliomas in elderly patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANAPLASTIC ASTROCYTOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant chemotherapy following surgery in patients with anaplastic astrocytoma is less clear than for those with glioblastoma. The phase III trials that established the survival benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    were limited to patients with GBM. In the only phase III trial limited to patients with anaplastic astrocytoma, adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    plus dibromodulcitol did not significantly increase overall survival compared with with RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/17\">",
"     17",
"    </a>",
"    ]. There are no randomized trials that evaluate the role of adjuvant chemotherapy in addition to RT in patients with anaplastic astrocytomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adjuvant temozolomide plus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    appears to be active in patients with anaplastic astrocytomas as well as GBMs. In a retrospective analysis of 109 patients with pathologically confirmed anaplastic astrocytoma derived from two consecutive trials, adjuvant temozolomide was as effective and less toxic than PCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/18\">",
"     18",
"    </a>",
"    ]. All patients had surgical resection followed by involved field RT (60 Gy in 30 fractions). Among the 60 patients treated with temozolomide, there were no significant differences in the two-year progression-free survival (59 versus 58 percent in patients treated with PCV) or the median progression-free survival (36 versus 34 months). Adjuvant chemotherapy was discontinued prematurely less often with temozolomide than PCV because of toxicity (0 versus 37 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy with delayed RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy was compared to adjuvant RT in a phase III trial (NOA-4), in which 318 patients were randomly assigned to adjuvant RT, with chemotherapy deferred until progression, or to adjuvant chemotherapy, with RT deferred until progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/19\">",
"     19",
"    </a>",
"    ]. Chemotherapy, either as the initial treatment or after progression following RT, was based upon a random assignment to either PCV or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . The primary endpoint was time to treatment failure.",
"   </p>",
"   <p>",
"    Patients with anaplastic astrocytomas, anaplastic oligoastrocytomas, and oligodendrogliomas comprised 53, 33, and 14 percent of cases, respectively. Pathology was reviewed centrally, and tumors with only minute or ambiguous features of oligodendroglial differentiation were classified as anaplastic astrocytomas.",
"   </p>",
"   <p>",
"    At a maximum follow-up of 54 months with less than 50 percent of patients having reached the primary endpoint, key findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no statistically significant difference in the median time to treatment failure, the primary endpoint of the trial, between those given RT first and those initially managed with chemotherapy (43 versus 44 months). This absence of a difference was observed in patients with anaplastic astrocytomas, anaplastic oligoastrocytomas, and oligodendrogliomas.",
"     </li>",
"     <li>",
"      There were no significant differences in time to treatment failure between patients assigned to PCV compared with those assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients with anaplastic astrocytomas did substantially worse than those with anaplastic oligoastrocytomas or oligodendrogliomas (hazard ratio [HR] for time to treatment failure for anaplastic astrocytomas versus anaplastic oligoastrocytomas and oligodendrogliomas both 3.3). There was no difference in outcome between anaplastic oligoastrocytomas and oligodendrogliomas (HR 1.0). In all three histologic subsets, no significant difference in time to treatment failure was observed with the two treatment sequences.",
"     </li>",
"     <li>",
"      Molecular markers that were associated with an improved prognosis on multivariate analysis included methylation of the MGMT promoter, codeletion of",
"      <span class=\"nowrap\">",
"       1p/19q,",
"      </span>",
"      and mutation of IDH1. The prognostic significance of these markers was independent of whether the patient was initially treated with RT or chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44103?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical features, pathology, and prognostic factors for oligodendroglial tumors\", section on 'Prognostic factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OLIGODENDROGLIAL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with grade III oligodendroglial tumors have a better prognosis than those with anaplastic astrocytomas. The use of postoperative RT and chemotherapy in patients with grade II and grade III oligodendroglial tumors is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11655?source=see_link&amp;anchor=H175763196#H175763196\">",
"     \"Treatment of oligodendroglial tumors\", section on 'Postoperative therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MGMT EXPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methyl guanine methyl transferase (MGMT) is an enzyme that is responsible for DNA-repair following alkylating agent chemotherapy. In the course of tumor development, the MGMT gene may be silenced by methylation of its promoter, thereby preventing repair of DNA damage and increasing the potential effectiveness of chemotherapy.",
"   </p>",
"   <p>",
"    Several clinical studies have indicated that MGMT promoter methylation is associated with improved survival in patients receiving adjuvant chemotherapy, including the large",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    adjuvant chemotherapy trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This prognostic role for MGMT has also been observed in studies in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Temozolomide'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In grade III glioma, MGMT promoter methylation also identifies patients who respond to RT alone (&ldquo;prognostic&rdquo;). In this histology, MGMT promoter methylation appears due to an IDH mutations induced CpG island hypermethyation phenotype, and the improved outcome is related to the improved outcome of IDH mutated tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of methylation of the MGMT promoter may also influence the patterns of clinical relapse. This was illustrated by a study of 95 patients treated with RT and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/25\">",
"     25",
"    </a>",
"    ]. At a median follow-up of 19 months, patients with methylated MGMT had a longer time to initial relapse and were more likely to relapse outside the RT treatment field (8 of those 17 versus 9 of 60 with an unmethylated primary tumor).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RESPONSE AND PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient management decisions require an assessment of both initial response to treatment as well as subsequent evidence of progressive disease. Traditionally, this approach has used the Macdonald criteria which rely upon measurement of areas of contrast enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/26\">",
"     26",
"    </a>",
"    ]. New criteria have been proposed by the Response Assessment in Neuro-Oncology (RANO) working group to address problems in assessing patients with pseudoprogression or in assessing progressive disease in patients with nonenhancing lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4821?source=see_link\">",
"     \"Assessment of disease status and surveillance after treatment in patients with brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H701993649\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no formal clinical trials that define the optimal frequency for follow-up after treatment. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend that a repeat MRI should be obtained in patients with a malignant glioma about four weeks after completion of radiation therapy, then every two to four months for two to three years, and less frequently thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/28/22978?source=see_link\">",
"       \"Patient information: Glioblastoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/52/8004?source=see_link\">",
"       \"Patient information: High-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a newly-diagnosed malignant glioma (including both glioblastoma (GBM) and grade III malignant glioma), maximal surgical resection consistent with preservation of neurologic function is the initial step in management. Although gross total resection is preferred whenever possible, subtotal resection or stereotactic biopsy may be required depending upon the location and extent of the tumor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a newly-diagnosed GBM, we recommend combined adjuvant radiation therapy (RT) and chemotherapy following surgery or biopsy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Glioblastoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a newly-diagnosed anaplastic astrocytoma, we generally suggest adjuvant radiation therapy (RT) and chemotherapy following surgery or biopsy, using the same approach to RT and chemotherapy as in patients with GBM (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=see_link\">",
"       \"Adjuvant radiation therapy for malignant gliomas\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Anaplastic astrocytoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest chemotherapy with single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      , rather than a nitrosourea-based regimen, because of its ease of administration and better patient tolerance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Temozolomide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of adjuvant chemotherapy in elderly patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15029?source=see_link&amp;anchor=H465209#H465209\">",
"       \"Management of malignant gliomas in elderly patients\", section on 'Contemporary randomized trials'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      These recommendations for the management of patients with newly diagnosed glioblastoma are consistent with guidelines published by the American Association of Neurological Surgeons and the Congress of Neurological Surgeons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42391/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/1\">",
"      Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/2\">",
"      Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/3\">",
"      Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/4\">",
"      Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23:2372.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     Temodar (temozolomide) prescribing information. file://www.merck.com/product/usa/pi_circulars/t/temodar_capsules/temodar_pi.pdf (Accessed on February 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/7\">",
"      Gilbert MR. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide with a dose-dense schedule in newly diagnosed glioblastoma. J Clin Oncol 2011; :141s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/8\">",
"      Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28:4601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/9\">",
"      Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/10\">",
"      Huncharek M, Muscat J, Geschwind JF. Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis. Anticancer Res 1998; 18:4693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/11\">",
"      Weller M, M&uuml;ller B, Koch R, et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003; 21:3276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/12\">",
"      Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/13\">",
"      Dixit S, Hingorani M, Achawal S, Scott I. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat Oncol Biol Phys 2011; DOI: 10.1016/j.ijrobp.2010.11.073). Int J Radiat Oncol Biol Phys 2011; 81:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/14\">",
"      Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: two case studies. Neuro Oncol 2005; 7:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/15\">",
"      Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29:142.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/17\">",
"      Hildebrand J, Gorlia T, Kros JM, et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer 2008; 44:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/18\">",
"      Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006; 8:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/19\">",
"      Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27:5874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/20\">",
"      Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/21\">",
"      Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/22\">",
"      Brandes AA, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009; 115:3512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/23\">",
"      Gerstner ER, Yip S, Wang DL, et al. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009; 73:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/24\">",
"      van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 2011; 17:7148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/25\">",
"      Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol 2009; 27:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/26\">",
"      Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/27\">",
"      Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/29\">",
"      Fadul CE, Wen PY, Kim L, Olson JJ. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol 2008; 89:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/30\">",
"      Buatti J, Ryken TC, Smith MC, et al. Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J Neurooncol 2008; 89:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42391/abstract/31\">",
"      Ryken TC, Frankel B, Julien T, Olson JJ. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J Neurooncol 2008; 89:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5207 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42391=[""].join("\n");
var outline_f41_25_42391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13374802\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGICAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ADJUVANT RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GLIOBLASTOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Temozolomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nitrosoureas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Systemic nitrosoureas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Carmustine polymer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360536\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANAPLASTIC ASTROCYTOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adjuvant temozolomide plus RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adjuvant chemotherapy with delayed RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OLIGODENDROGLIAL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MGMT EXPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ASSESSMENT OF RESPONSE AND PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701993649\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5207|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/15/23804\" title=\"table 1\">",
"      PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/45/2780\" title=\"table 2\">",
"      Chemo regimens brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4712?source=related_link\">",
"      Adjuvant radiation therapy for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4821?source=related_link\">",
"      Assessment of disease status and surveillance after treatment in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44103?source=related_link\">",
"      Clinical features, pathology, and prognostic factors for oligodendroglial tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19674?source=related_link\">",
"      Experimental treatment approaches for malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15029?source=related_link\">",
"      Management of malignant gliomas in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/28/22978?source=related_link\">",
"      Patient information: Glioblastoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11655?source=related_link\">",
"      Treatment of oligodendroglial tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_25_42392="Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor";
var content_f41_25_42392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42392/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42392/contributors\">",
"     Wendell F Rosse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42392/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42392/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42392/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42392/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/25/42392/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal nocturnal hemoglobinuria (PNH) was one of the first hematologic disorders given a clear clinical description, because the defining symptom, dark urine at night, was distinctive and easily observed. It was subsequently realized that the pigment was hemoglobin, which resulted from the breakdown or hemolysis of red cells.",
"   </p>",
"   <p>",
"    The hemolysis was found to be due to the action of complement on abnormal red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Compared with normal cells, PNH cells were lysed more readily when complement was activated by antibody. This property was used for many years to define the abnormal red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recognition that the red cells of patients with PNH were abnormal led to many attempts to determine the biochemical basis of these changes. The first abnormalities found were the deficiency of two enzymes, leukocyte alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/4\">",
"     4",
"    </a>",
"    ] and erythrocyte acetylcholinesterase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/5\">",
"     5",
"    </a>",
"    ]; however, the absence of neither protein explained the clinical symptoms of PNH.",
"   </p>",
"   <p>",
"    Subsequently, decay accelerating factor (DAF, CD55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/6\">",
"     6",
"    </a>",
"    ], and the membrane inhibitor of reactive lysis (MIRL, CD59) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/7\">",
"     7",
"    </a>",
"    ], both complement regulatory proteins, were also found to be absent, findings which explained the unusual sensitivity of PNH red cells to the hemolytic action of complement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these proteins are tethered to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. This finding uncovered the fundamental pathogenic defect in PNH: the inability to produce the GPI anchor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the role of absence of the GPI anchor in PNH, beginning with a brief discussion of the biochemistry and genetics of this anchor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The role of the missing cell proteins, such as CD55 and CD59, in the pathogenesis of PNH is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13593?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed history of our evolving understanding of PNH has been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membrane proteins were once believed to be integrally affixed to the external surface of the plasma membrane in only one way: a linear array of hydrophobic amino acids that interacted with the lipid bilayer. However, the possibility of another membrane anchor was suggested by the finding that surface-bound alkaline phosphatase could be removed by a bacterial enzyme, phosphatidylinositol-specific phospholipase C (PIPLC), which cleaved the phosphate from phosphatidylinositol but did not cleave peptide bonds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/12\">",
"     12",
"    </a>",
"    ]; in addition, alkaline phosphatase had full activity after its release, indicating that the protein structure had not been altered. This observation led to the identification of a glycan-containing anchor which attached to the carboxyl end of the peptide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Molecular structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GPI anchor consists of a molecule of phosphatidylinositol (PI), a glycan core consisting of a molecule of N-glucosamine and three molecules of mannose, and a molecule of ethanolamine (ETN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/9\">",
"     9",
"    </a>",
"    ]. On the cell surface, the PI end of the anchor is inserted into the lipid bilayer of the plasma membrane and the ETN end is attached by an amide bond to the carboxyl end of a protein molecule.",
"   </p>",
"   <p>",
"    The glycan portion of the molecule consists of a molecule of N-glucosamine (GluN), which is attached by a (1-6) linkage to the inositol. To this are linked three mannose molecules attached by different glycosidic links. The terminal mannose is linked to a phosphoethanolamine moiety through its sixth carbon, thereby exposing the amine for reaction with the carboxyl end of the protein to be attached. Some minor variations of this principal structural schema exist across species.",
"   </p>",
"   <p>",
"    As noted above, one of the defining characteristics of the GPI anchor is its ability to be cleaved by a specific bacterial enzyme, phosphatidylinositol-specific phospholipase C (PIPLC), which is derived from Staphylococcus aureus, Bacillus cereus and other organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The activity of this protein is often used to determine whether a protein is GPI-linked. However, PIPLC is inactive against most mammalian GPI structures, as they are usually acylated with a palmityl moiety attached to the inositol. Another phospholipase, PIPLD, is capable of cleaving the glycan from the PI, even when this is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Biosynthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GPI anchor is synthesized in the endoplasmic reticulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/9\">",
"     9",
"    </a>",
"    ]. This is a complex process but a review of the initial steps is important for understanding the defect in PNH. The construction of the glycan core begins with the enzymatic addition of a molecule of N-acetylglucosamine in a 1-6 linkage to the inositol on PI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of the first sugar to PI is not simple, since at least three gene products are involved either in or in preparation for this step. This conclusion is derived from the observation that three different murine cell lines, designated classes A, C and H, are deficient in this ability; however, a fused cell, consisting of a fusion between a cell from two of these cell lines, is able to perform this task, thereby indicating that each cell line is deficient in a different way, and thus complementary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gene product missing in class A appears to be a glycosyltransferase (presumably one with specificity for N-acetylglucosamine), as suggested by structural homology to other glycosyltransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/19\">",
"     19",
"    </a>",
"    ]. At least seven gene products are required for this complex initial step [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After its addition to PI, the molecule of N-acetylglucosamine is enzymatically deacetylated, a reaction that is enhanced by the presence of GTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/21\">",
"     21",
"    </a>",
"    ]; if this step does not occur, further synthesis of the anchor is stopped. This abnormality is defined as the class J defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DEFECTS IN SYNTHESIS OF THE GPI ANCHOR IN PNH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that all the proteins missing in the hematopoietic cells in PNH were attached to the membrane by the GPI anchor suggested that the abnormality in the hematopoietic cells in this disease results from either a defect in synthesis of the GPI anchor or excessive removal of these proteins by an overactive phospholipase. The possibility of a biosynthetic defect was investigated by two methods:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Examination of the GPI intermediates in the PNH cells",
"     </li>",
"     <li>",
"      Fusion of PNH cells with the various cell lines in which the defect was known to determine if the defects are complementary",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     GPI intermediates in PNH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A biosynthetic defect was sought by labeling the intermediates of GPI anchor synthesis with radiolabeled mannose, N-acetylglucosamine, or phosphoethanolamine, techniques that had been used to outline the biosynthesis of the anchor in trypanosomes and mammalian cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Although initial studies demonstrated that the complete anchor was not synthesized, these and later reports were complicated by the fact that (in many patients) the defective cells were either difficult to isolate or made small amounts of intermediates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/25\">",
"     25",
"    </a>",
"    ]. More refined studies (primarily from cultured cell lines) then demonstrated that no mannosylated derivatives were made, and that N-acetylglucosamine was not incorporated into the anchor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cell fusion experiments",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, defective incorporation of N-acetylglucosamine into the biosynthetic pathway has been observed in three different complementing GPI-defective classes: A, C, and H. Somatic cell fusion studies, in which either cultured cells (usually EBV-transformed B lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]) or abnormal granulocytes from the peripheral blood of patients with PNH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/31\">",
"     31",
"    </a>",
"    ] were fused with the murine cell lines, demonstrated the importance of the",
"    <strong>",
"     class A defect",
"    </strong>",
"    . In all cases, the cells of class A did not complement the abnormal PNH cells, whereas the cells of all other classes did [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This finding established that the defect in GPI anchor synthesis in PNH was the same as in class A defective lymphocytes. The genetic locus for this defect is the PIG-A gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THE PIG-A GENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A defect in the PIG-A gene in hematopoietic stem cells appears to be a necessary condition for the development of PNH. However, it is not clear if the defect is sufficient for the manifestation of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/9\">",
"     9",
"    </a>",
"    ], especially since PIG-A mutations have been found in CD34+ progenitor cells in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/33\">",
"     33",
"    </a>",
"    ]. Alterations in hematopoiesis unrelated to the defect may be necessary to permit the defective cells to proliferate preferentially in the bone marrow. Nevertheless, the disease is defined clinically by the effects of a defective PIG-A gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     cDNA cloning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defective cDNA in PNH was isolated by expression cloning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. The translated protein is 484 amino acids in length and does not appear to have an amino-terminal signal sequence, suggesting that it is external to the endoplasmic reticulum cisterna. The protein also has a hydrophobic region near the carboxyl end consisting of 27 amino acids, a structure suggestive of a transmembrane region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the cDNA has been cloned, the protein has not yet been isolated or otherwise characterized, and its exact role in GPI anchor synthesis is not known. However, the derived amino acid sequence has considerable homology to a family of glycosyltransferases, particularly near the amino terminus. One member of this family found in yeast, SPT14, has more than 45 percent homology to human PIG-A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/35\">",
"     35",
"    </a>",
"    ]. SPT14 is apparently the exact analogue in that it is necessary for the transfer of N-acetylglucosamine to the nascent GPI anchor of yeast and its absence causes marked abnormalities in the biology of the organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/35\">",
"     35",
"    </a>",
"    ]. These studies indicate that the role of the PIG-A protein is probably the direct transfer of the sugar moiety to inositol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genomic clones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genomic clones of human PIG-A have been isolated and characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/19,36\">",
"     19,36",
"    </a>",
"    ]. The gene contains 6 exons and 5 introns and extends over at least 17 kilobases. The murine version of the PIG-A gene has also been cloned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/37\">",
"     37",
"    </a>",
"    ], and has been used to attempt to make a genetically deficient mouse by homologous recombination. However, only somatic chimeras with a maximum of 15 percent abnormal cells have thus far been produced. These and other findings suggest that the fully developed PIG-A knockout is lethal in utero.",
"   </p>",
"   <p>",
"    A family has been identified with an X-linked lethal disorder characterized by cleft palate, neonatal seizures, contractures, CNS abnormalities and other anomalies; those affected have a variant gene for PIG-A which results in a missense copy and a protein that is reduced in biosynthesis or function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lineage specific knockout of the PIG-A gene in mice has been achieved, using the Cre-Lox system to limit the abnormality to the hematopoietic cells, especially red cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/39\">",
"     39",
"    </a>",
"    ]. These studies showed that the animals maintained the proportion of GPI-negative cells that they were born with; the defect did not lead to a proliferative advantage. Further, mice with nearly 100 percent abnormal red cells did not have significant hemolytic anemia, because mice have a complement defense protein, Crry, which is not GPI-linked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Abnormalities in PNH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery that the PIG-A gene is abnormal in PNH set off a flurry of investigations to delineate the specific abnormalities that result in clinical disease. Approximately 80 to 90 abnormalities have been described and several patterns have emerged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/32,40-49\">",
"     32,40-49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of the defects involve a \"frame-shift\" abnormality that usually ends with a premature stop codon, thereby resulting in the lack of a protein product.",
"     </li>",
"     <li>",
"      Substitution mutations are concentrated in two regions in exon 2, areas which are strongly conserved across species (and homologous even in yeast and protozoa). These alterations appear to result in proteins that are less effective in the biosynthesis of the GPI anchor, causing intermediate levels of GPI-anchored proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/40,48,49\">",
"       40,48,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With few exceptions, the mutations are unique to a patient; only seven of the mutations have been found in more than one individual. This finding suggests the absence of a mutational \"hot spot\" within the gene.",
"     </li>",
"     <li>",
"      Multiple clones have been found in a number of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/40,42,44\">",
"       40,42,44",
"      </a>",
"      ]. In this setting, one clone often has no protein product, while the other produces a defective protein that results in diminished production of the GPI anchor. This combination gives rise to two populations of cells that differ both in the expression of GPI-linked proteins (particularly CD59) and in their sensitivity to complement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of defects in the PIG-A gene is unclear. The occurrence of multiple clones in several patients suggests either that the rate of mutation of the gene is very high or that certain individuals have a marked tendency to such mutations. Studies are currently underway to determine if other genes in these individuals are also mutated at a higher rate than normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also possible that the bone marrow environment promotes the emergence of PNH clones. Two observations are consistent with this hypothesis. First, recurrence of PNH after bone marrow or stem cell transplantation appears to occur only in recipients of identical twin (syngeneic) transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/51\">",
"     51",
"    </a>",
"    ]. Second, recurrence in one such recipient was due to emergence of a new clone, rather than persistence of the original clone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mechanism of mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As opposed to germ-line genetic defects, it is unusual that many of the somatic genetic defects in PNH involve the insertion or deletion of non-triple nucleotides. In bacterial genetics, such defects have been ascribed to deficiencies of repair during DNA replication. Since polymerases proceed only 5' to 3', replication can proceed continuously down the strand of only one (the leading strand) of the two strands being replicated as DNA is unwound. The other strand must be replicated in short segments of several hundred to several thousand base pairs; these segments must then be ligated together to form the continuous duplicated strand.",
"   </p>",
"   <p>",
"    It is hypothesized that the finding of addition or subtraction of one or two nucleotides in PNH occurs because of errors in this ligation process. Such a mechanism would explain the frequent occurrence of PNH without any preceding mutagenic event, which is seldom identified in patients with PNH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF PNH: MULTISTEP HYPOTHESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all patients with PNH have a population of GPI-deficient blood cells, this fact alone is insufficient to explain the onset of the disease. In the first place, such cells have been found in many if not most normal individuals in very small numbers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/33,52\">",
"     33,52",
"    </a>",
"    ]. Their numbers are increased in patients with aplastic anemia, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/53\">",
"     53",
"    </a>",
"    ] and in some cases become so large as to result in clinical PNH.",
"   </p>",
"   <p>",
"    However, in animal models, expansion of the abnormal clone is apparently not related to the lack of GPI-anchored proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/54\">",
"     54",
"    </a>",
"    ]. Further, the deficiency in cell production, often manifest in PNH, is not due to the lack of GPI-linked proteins, and bone marrow culture studies of most, if not all, patients demonstrate hypoproliferation of all cell lines both with and without the GPI anchor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/55-59\">",
"     55-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above-noted facts have led to the multistep (Luzzatto-Young) hypothesis of the pathogenesis of PNH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. This theory states that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The somatic mutation resulting in the loss of expression of GPI-anchored proteins occurs in a small number of hematopoietic stem cells in many, if not most, normal individuals. However, these clones do not proliferate greatly, probably because of this defect.",
"     </li>",
"     <li>",
"      When proliferation of normal cells of the bone marrow is suppressed by processes that cause aplastic anemia, these defective cells are less affected than the cells bearing GPI-linked proteins. These processes are thought to be immunologic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/62\">",
"       62",
"      </a>",
"      ]. This results in the preferential selection of the defective cells characteristic of PNH.",
"     </li>",
"     <li>",
"      The selected clones are expanded by processes not well understood, resulting in sufficient numbers of defective cells, along with the clinical manifestations of PNH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clonal Selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PNH have clinical evidence of deficient production of hematopoietic cells. Dacie and Lewis first noted the relationship between PNH and aplastic anemia (AA), as well as defective hematopoiesis in PNH without manifest AA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/63\">",
"     63",
"    </a>",
"    ]. Since the survival in the peripheral circulation of granulocytes and platelets is normal in PNH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], the frequent occurrence of reduced numbers of these cells leads one to conclude that their production is deficient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=see_link\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro studies have confirmed these clinical findings. In almost all cases, the proliferation of colonies of precursors in PNH marrow is diminished when compared with normal precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. Both the GPI-negative and GPI-positive cells are affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/60\">",
"     60",
"    </a>",
"    ], but the GPI-negative cells appear to have some advantage, as they are found in larger numbers than normal in patients newly diagnosed with AA.",
"   </p>",
"   <p>",
"    The cause of the hematopoietic suppression in idiopathic aplastic anemia is considered to be immunologic in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/67\">",
"     67",
"    </a>",
"    ]; this mechanism might also be operative in PNH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Diminished suppression of PNH cells could occur if the receptor for a suppressive hematopoietic cytokine, such as transforming growth factor-beta, were GPI-linked and therefore missing, or if a GPI-linked interactive protein, such as LFA-3, mediated cytotoxic cellular interactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative explanation is that PIG-A mutations directly confer a survival advantage by making the cells relatively resistant to apoptotic death, as compared with their non-mutated counterparts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Resistance to apoptosis was reversed in one study by replacement of the normal PIG-A gene in PNH cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/71\">",
"     71",
"    </a>",
"    ]. In another report, however, resistance to apoptosis was not related to the PIG-A mutation, suggesting that this is not the mechanism for the clonal dominance of PNH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/74\">",
"     74",
"    </a>",
"    ]. Resolving this issue will be important, since correction of the genetic defect in PNH cells by gene therapy could expose the corrected cells to the original insult causing bone marrow failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interesting clinical observation was made when patients with lymphoma were treated with a cytotoxic monoclonal antibody against Campath-1 (CDw52), one of the proteins missing in PNH. Several of the patients had the transient appearance of GPI-deficient cells in the blood, suggesting that these cells were selected by a process which affected cells bearing a protein that they lacked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clonal Expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of the hematopoietic clone lacking GPI-linked proteins is not sufficient for the development of clinical PNH; an additional event or events must cause that clone to expand. As an example, up to 68 percent of patients with newly-diagnosed aplastic anemia have increased numbers of cells lacking GPI-linked proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/53\">",
"     53",
"    </a>",
"    ], but in fewer than 15 percent does the number of these cells increase to the point that the manifestations of PNH become clear. Animal experiments in which a PNH-like population of cells is induced by genetic manipulation also show that the lack of the GPI-proteins by itself does not cause expansion of the clone; the proportion of cells remains stable for prolonged periods of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To date, little evidence has been brought to bear explaining this clonal expansion in PNH. It might be explained by a resistance to apoptosis, although this characteristic is shared with the bone marrow cells in aplastic anemia. Changes in other genes associated with cellular proliferation (Wilms' tumor gene, WT1) have been suggested to cause the clonal expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most interesting of these potentially altered genes is HMGA2. In two patients, a chromosomal break in chromosome 12 led to the finding of an alteration in the HMGA2 gene, the architectural transcription factor gene deregulated in many benign mesenchymal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/78\">",
"     78",
"    </a>",
"    ]; this deregulation is usually due to truncation at the 3&rsquo; untranslated region, the site of binding of the regulatory micro RNA let-7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/79\">",
"     79",
"    </a>",
"    ]. Further studies have shown that truncation resulting in expression of a short HMGA2 was present in 18 of 24 patients with PNH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42392/abstract/80\">",
"     80",
"    </a>",
"    ]. This has led to the proposal that the clonal expansion, at least in these cases, was due to a controlled increase in proliferation resulting from a defective gene, which is somatically mutated. Since detectable chromosomal abnormalities are not common in PNH, the search for such defective gene(s) in other subjects will be difficult.",
"   </p>",
"   <p>",
"    Thus, the occurrence of PNH appears to be due to two processes: a selection process whereby the cells lacking the GPI anchor have an increased survival, and an expansion process whereby the selected clone undergoes controlled increased proliferation. Both of these processes are imprecisely understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10579125\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental pathogenic defect in paroxysmal nocturnal hemoglobinuria (PNH) is the inability to produce the glycosylphosphatidylinositol (GPI) anchor, to which many important proteins are attached. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13593?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\", section on 'Missing proteins in PNH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The GPI anchor is synthesized through a multistep process. A defect in the PIG-A gene in hematopoietic stem cells appears to be a necessary condition for the development of PNH. The PIG-A protein acts as a glycosyl transferase in this process. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glycosylphosphatidylinositol anchor'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Defects in synthesis of the GPI anchor in PNH'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'The PIG-A gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement regulatory proteins are among these GPI-tethered proteins, explaining the unusual sensitivity of PNH red cells to the hemolytic action of complement. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\", section on 'Hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The somatic mutation in the PIG-A gene occurs in a small number of hematopoietic stem cells. Preferential selection (clonal expansion) of the defective cells occurs via processes not well understood, resulting in sufficient numbers of defective cells, along with the clinical manifestations of PNH. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathogenesis of PNH: multistep hypothesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/1\">",
"      Ham TH. Chronic hemolytic. A study of the mechanism of hemolysis in relation to acid-base equilibrium. N Engl J Med 1938; 217:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/2\">",
"      Ham TH, Dingle JH. STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT. J Clin Invest 1939; 18:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/3\">",
"      Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest 1966; 45:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/4\">",
"      Lewis SM, Dacie JV. Neutrophil (leucocyte) alkaline phosphatase in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1965; 11:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/5\">",
"      AUDITORE JV, HARTMANN RC, FLEXNER JM, BALCHUM OJ. The erythrocyte acetylcholinesterase enzyme in paroxysmal nocturnal hemoglobinuria. Arch Pathol 1960; 69:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/6\">",
"      Nicholson-Weller A, Burge J, Fearon DT, et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982; 129:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/7\">",
"      Holguin MH, Parker CJ. Membrane inhibitor of reactive lysis. Curr Top Microbiol Immunol 1992; 178:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/8\">",
"      Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med 1986; 163:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/9\">",
"      Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997; 76:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/10\">",
"      Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2000; 108:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/11\">",
"      Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: 'defining the disease'. Br J Haematol 2002; 117:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/12\">",
"      Low MG, Finean JB. Release of alkaline phosphatase from membranes by a phosphatidylinositol-specific phospholipase C. Biochem J 1977; 167:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/13\">",
"      Ikezawa H, Yamanegi M, Taguchi R, et al. Studies on phosphatidylinositol phosphodiesterase (phospholipase C type) of Bacillus cereus. I. purification, properties and phosphatase-releasing activity. Biochim Biophys Acta 1976; 450:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/14\">",
"      Davitz MA, Hereld D, Shak S, et al. A glycan-phosphatidylinositol-specific phospholipase D in human serum. Science 1987; 238:81.",
"     </a>",
"    </li>",
"    <li>",
"     Low MG. Structure and function of GPI-specific phospholipases. In: PNH and the GPI-linked proteins, Young NS, Moss J (Eds), Academic Press, 2000. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/16\">",
"      Masterson WJ, Doering TL, Hart GW, Englund PT. A novel pathway for glycan assembly: biosynthesis of the glycosyl-phosphatidylinositol anchor of the trypanosome variant surface glycoprotein. Cell 1989; 56:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/17\">",
"      Stevens VL, Raetz CR. Defective glycosyl phosphatidylinositol biosynthesis in extracts of three Thy-1 negative lymphoma cell mutants. J Biol Chem 1991; 266:10039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/18\">",
"      Sugiyama E, DeGasperi R, Urakaze M, et al. Identification of defects in glycosylphosphatidylinositol anchor biosynthesis in the Thy-1 expression mutants. J Biol Chem 1991; 266:12119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/19\">",
"      Bessler M, Hillmen P, Longo L, et al. Genomic organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal haemoglobinuria and of a related autosomal pseudogene mapped to 12q21. Hum Mol Genet 1994; 3:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/20\">",
"      Murakami Y, Siripanyaphinyo U, Hong Y, et al. The initial enzyme for glycosylphosphatidylinositol biosynthesis requires PIG-Y, a seventh component. Mol Biol Cell 2005; 16:5236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/21\">",
"      Stevens VL. Regulation of glycosylphosphatidylinositol biosynthesis by GTP. Stimulation of N-acetylglucosamine-phosphatidylinositol deacetylation. J Biol Chem 1993; 268:9718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/22\">",
"      Hirose S, Mohney RP, Mutka SC, et al. Derivation and characterization of glycoinositol-phospholipid anchor-defective human K562 cell clones. J Biol Chem 1992; 267:5272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/23\">",
"      Englund PT. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem 1993; 62:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/24\">",
"      Ferguson MA, Williams AF. Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures. Annu Rev Biochem 1988; 57:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/25\">",
"      Mahoney JF, Urakaze M, Hall S, et al. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood 1992; 79:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/26\">",
"      Hillmen P, Bessler M, Mason PJ, et al. Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 1993; 90:5272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/27\">",
"      Hirose S, Ravi L, Prince GM, et al. Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A 1992; 89:6025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/28\">",
"      Takahashi M, Takeda J, Hirose S, et al. Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1993; 177:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/29\">",
"      Hillmen P, Bessler M, Crawford DH, Luzzatto L. Production and characterization of lymphoblastoid cell lines with the paroxysmal nocturnal hemoglobinuria phenotype. Blood 1993; 81:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/30\">",
"      Ueda E, Nishimura J, Kitani T, et al. Deficient surface expression of glycosylphosphatidylinositol-anchored proteins in B cell lines established from patients with paroxysmal nocturnal hemoglobinuria. Int Immunol 1992; 4:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/31\">",
"      Norris J, Hall S, Ware RE, et al. Glycosyl-phosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria: partial or complete defect in an early step. Blood 1994; 83:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/32\">",
"      Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/33\">",
"      Hu R, Mukhina GL, Piantadosi S, et al. PIG-A mutations in normal hematopoiesis. Blood 2005; 105:3848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/34\">",
"      Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/35\">",
"      Vossen JH, Ram AF, Klis FM. Identification of SPT14/CWH6 as the yeast homologue of hPIG-A, a gene involved in the biosynthesis of GPI anchors. Biochim Biophys Acta 1995; 1243:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/36\">",
"      Iida Y, Takeda J, Miyata T, et al. Characterization of genomic PIG-A gene: a gene for glycosylphosphatidylinositol-anchor biosynthesis and paroxysmal nocturnal hemoglobinuria. Blood 1994; 83:3126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/37\">",
"      Kawagoe K, Takeda J, Endo Y, Kinoshita T. Molecular cloning of murine pig-a, a gene for GPI-anchor biosynthesis, and demonstration of interspecies conservation of its structure, function, and genetic locus. Genomics 1994; 23:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/38\">",
"      Johnston JJ, Gropman AL, Sapp JC, et al. The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria. Am J Hum Genet 2012; 90:295.",
"     </a>",
"    </li>",
"    <li>",
"     Bessler M, Kulkarni S, Jasinski M, et al. Mice with blood cells defcient in GPI-linked proteins - the generation of a murine model to investigate the pathogenesis and pathophysiology of paroxysmal nocturnal hemoglobinuria. In: Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis, Omine M, Kinoshita T (Eds), Springer, Tokyo  p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/40\">",
"      Bessler M, Mason P, Hillmen P, Luzzatto L. Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet 1994; 343:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/41\">",
"      Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J 1994; 13:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/42\">",
"      Endo M, Ware RE, Vreeke TM, et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood 1996; 87:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/43\">",
"      Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994; 330:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/44\">",
"      Nafa K, Mason PJ, Hillmen P, et al. Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type. Blood 1995; 86:4650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/45\">",
"      Nagarajan S, Brodsky RA, Young NS, Medof ME. Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood 1995; 86:4656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/46\">",
"      Ostendorf T, Nischan C, Schubert J, et al. Heterogeneous PIG-A mutations in different cell lineages in paroxysmal nocturnal hemoglobinuria. Blood 1995; 85:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/47\">",
"      Pramoonjago P, Wanachiwanawin W, Chinprasertsak S, et al. Somatic mutations of PIG-A in Thai patients with paroxysmal nocturnal hemoglobinuria. Blood 1995; 86:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/48\">",
"      Ware RE, Rosse WF, Howard TA. Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 1994; 83:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/49\">",
"      Nafa K, Bessler M, Castro-Malaspina H, et al. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/50\">",
"      Horikawa K, Kawaguchi T, Ishihara S, et al. Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 2002; 99:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/51\">",
"      Nafa K, Bessler M, Deeg HJ, Luzzatto L. New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria. Blood 1998; 92:3422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/52\">",
"      Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 1999; 96:5209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/53\">",
"      Mukhina GL, Buckley JT, Barber JP, et al. Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. Br J Haematol 2001; 115:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/54\">",
"      Araten DJ, Bessler M, McKenzie S, et al. Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones. Leukemia 2002; 16:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/55\">",
"      Issaragrisil S, Piankijagum A, Chinprasertsuk S, Kruatrachue M. Growth of mixed erythroid-granulocytic colonies in culture derived from bone marrow of patients with paroxysmal nocturnal hemoglobinuria without addition of exogenous stimulator. Exp Hematol 1986; 14:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/56\">",
"      Rickard KA, Brown RD, Wilkinson T, Kronenberg H. The colony forming cell in the myeloproliferative disorders and aplastic anaemia. Scand J Haematol 1979; 22:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/57\">",
"      Tumen J, Kline LB, Fay JW, et al. Complement sensitivity of paroxysmal nocturnal hemoglobinuria bone marrow cells. Blood 1980; 55:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/58\">",
"      Elebute MO, Rizzo S, Tooze JA, et al. Evaluation of the haemopoietic reservoir in de novo haemolytic paroxysmal nocturnal haemoglobinuria. Br J Haematol 2003; 123:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/59\">",
"      Karadimitris A, Araten DJ, Luzzatto L, Notaro R. Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPI- and GPI+ hematopoiesis. Blood 2003; 102:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/60\">",
"      Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 1996; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/61\">",
"      Young NS. The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood 1992; 79:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/62\">",
"      Alahmad A, Preuss KD, Schenk J, et al. Desmoplakin and KIF20B as target antigens in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010; 151:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/63\">",
"      DACIE JV, LEWIS SM. Paroxysmal nocturnal haemoglobinuria: variation in clinical severity and association with bone-marrow hypoplasia. Br J Haematol 1961; 7:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/64\">",
"      Brubaker LH, Essig LJ, Mengel CE. Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood 1977; 50:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/65\">",
"      Devine DV, Siegel RS, Rosse WF. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo. J Clin Invest 1987; 79:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/66\">",
"      DACIE JV. Paroxysmal nocturnal haemoglobinuria. Proc R Soc Med 1963; 56:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/67\">",
"      Young NS. Aplastic anaemia. Lancet 1995; 346:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/68\">",
"      Karadimitris A, Manavalan JS, Thaler HT, et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 2000; 96:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/69\">",
"      Tiu R, Maciejewski J. Immune pathogenesis of paroxysmal nocturnal hemoglobinuria. Int J Hematol 2006; 84:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/70\">",
"      Gargiulo L, Lastraioli S, Cerruti G, et al. Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 109:5036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/71\">",
"      Brodsky RA, Vala MS, Barber JP, et al. Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 1997; 94:8756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/72\">",
"      Chen R, Nagarajan S, Prince GM, et al. Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria. J Clin Invest 2000; 106:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/73\">",
"      Ismail MM, Tooze JA, Flynn JA, et al. Differential apoptosis and Fas expression on GPI-negative and GPI-positive stem cells: a mechanism for the evolution of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2003; 123:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/74\">",
"      Ware RE, Nishimura J, Moody MA, et al. The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood 1998; 92:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/75\">",
"      Bessler M, Hillmen P. Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria. Semin Hematol 1998; 35:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/76\">",
"      Rosti V, Tremml G, Soares V, et al. Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest 1997; 100:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/77\">",
"      Shichishima T, Noji H. Heterogeneity in the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) syndromes and expansion mechanism of a PNH clone. Int J Hematol 2006; 84:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/78\">",
"      Inoue N, Izui-Sarumaru T, Murakami Y, et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 2006; 108:4232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/79\">",
"      Ikeda K, Mason PJ, Bessler M. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 2011; 117:5860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42392/abstract/80\">",
"      Murakami Y, Inoue N, Shichishima T, et al. Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2012; 156:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7160 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-2110654F66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42392=[""].join("\n");
var outline_f41_25_42392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10579125\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Molecular structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DEFECTS IN SYNTHESIS OF THE GPI ANCHOR IN PNH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GPI intermediates in PNH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cell fusion experiments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THE PIG-A GENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      cDNA cloning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genomic clones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Abnormalities in PNH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mechanism of mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOGENESIS OF PNH: MULTISTEP HYPOTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clonal Selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clonal Expansion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10579125\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13593?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_25_42393="Nonspecific interstitial pneumonia";
var content_f41_25_42393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonspecific interstitial pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42393/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42393/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42393/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/25/42393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific interstitial pneumonia (NSIP) is one type of idiopathic interstitial pneumonia (IIP). The other IIPs include usual interstitial pneumonia",
"    <span class=\"nowrap\">",
"     (UIP)/idiopathic",
"    </span>",
"    pulmonary fibrosis,",
"    <span class=\"nowrap\">",
"     (IPF)/cryptogenic",
"    </span>",
"    fibrosing alveolitis (CFA), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis associated interstitial lung disease (RB-ILD), acute interstitial pneumonia (AIP), lymphocytic interstitial pneumonia (LIP), and cryptogenic organizing pneumonia",
"    <span class=\"nowrap\">",
"     (COP)/bronchiolitis",
"    </span>",
"    obliterans organizing pneumonia (BOOP).",
"   </p>",
"   <p>",
"    NSIP is \"nonspecific\" in that it presents similarly to other IIPs, but lacks the histopathologic features that characterize the individual disorders. In this review, the etiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of NSIP are discussed. The pathology of NSIP is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term NSIP has been associated with many medical conditions, although a causal link has not been identified. In addition, it may be idiopathic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSIP is frequently identified in patients who have AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. In one observational study of 110 patients with AIDS and interstitial lung disease, NSIP was detected in 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/1\">",
"     1",
"    </a>",
"    ]. Nearly half of the patients had normal chest radiographs. A study performed since the introduction of HAART found that 7 percent of HIV patients admitted with ILD had NSIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Connective tissue disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several connective tissue disorders including polymyositis-dermatomyositis, rheumatoid arthritis, Sj&ouml;gren&rsquo;s syndrome, and systemic sclerosis have been associated with NSIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/7-15\">",
"     7-15",
"    </a>",
"    ]. Although not all patients with ILD in the context of a known collagen vascular disease are biopsied, several studies have shown NSIP to be a common pattern.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common pulmonary presentation in an observational study of 70 patients with polymyositis-dermatomyositis (PD) and interstitial lung disease (ILD) was presumed acute or subacute antibiotic resistant community acquired pneumonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/10\">",
"       10",
"      </a>",
"      ]. NSIP was identified in 18 of 22 patients who underwent lung biopsy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24697?source=see_link\">",
"       \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among 16 patients with rheumatoid arthritis and ILD, 7 had features most consistent with NSIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Of nine patients with Sj&ouml;gren&rsquo;s syndrome and ILD, three had NSIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/32/16906?source=see_link\">",
"       \"Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In 80 patients with ILD associated with systemic sclerosis, NSIP was identified in 62 (77.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/12\">",
"       12",
"      </a>",
"      ]. In another study of patients with systemic sclerosis, 13 of 19 had NSIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=see_link\">",
"       \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presenting manifestation of systemic sclerosis sine scleroderma (a rare illness characterized by the typical vascular features and visceral fibrosis of systemic disease but without skin sclerosis) may be dyspnea with radiographic interstitial lung disease in a pattern of either NSIP or UIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients usually have subtle physical exam findings such as scattered telangiectasia, Raynaud's phenomenon, esophageal reflux, pericardial effusion, and abnormal nailfold capillaroscopy. Antinuclear antibodies are typically of the nucleolar pattern. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link&amp;anchor=H7#H7\">",
"       \"Classification of scleroderma disorders\", section on 'SSc sine scleroderma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      At least one of six patients with ILD in the context of microscopic polyangiitis had a lung biopsy showing NSIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients who have histologic NSIP have some features of connective tissue disease, but the findings are insufficient for definitive classification. In a case-control study of 28 patients with NSIP who had no clear underlying disease, 88 percent had laboratory or clinical features of undifferentiated connective tissue disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/18\">",
"     18",
"    </a>",
"    ]. These features included arthralgias, GERD, Raynaud's, sicca symptoms, and dysphagia, in addition to positive serologic studies (eg, rheumatoid factor, ANA, or antibodies to SSA, SSB, RNP, Jo-1, SCL-70). A larger study with prospectively collected data is needed to better define the relationship between \"idiopathic\" and \"connective tissue related\" NSIP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypersensitivity pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with hypersensitivity pneumonitis (also called extrinsic allergic alveolitis), surgical lung biopsy lacks the characteristic poorly formed granulomata and multinucleated giant cells and has an appearance more typical of NSIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/19\">",
"     19",
"    </a>",
"    ]. In patients with chronic bird fancier's lung, 13 of 26 had NSIP; most had some multinucleated giant cells, but only one-fourth had granulomata [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/49/19222?source=see_link\">",
"     \"Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drug-associated NSIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , statins, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    have been associated with an NSIP pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/21-26\">",
"     21-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The understanding of the pathogenesis of idiopathic NSIP and other IIPs is evolving. A potential relationship between NSIP and usual interstitial pneumonia (UIP) is suggested by the commonality of associated diseases, exposures, and genetic mutations, in addition to the observation that individual patients can harbor histopathologic lesions of both UIP and NSIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The exact nature of this association is not known.",
"   </p>",
"   <p>",
"    Epithelial injury and disregulated repair likely play a role in the pathogenesis of NSIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/29\">",
"     29",
"    </a>",
"    ]. Numerous cytokines that potentially play a role have been described including: epimorphin, a cell surface-associated protein involved in epithelial morphogenesis in embryonic organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/30\">",
"     30",
"    </a>",
"    ], matrix metalloproteinases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], heat shock protein 47 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/32\">",
"     32",
"    </a>",
"    ], surfactant protein C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/33-37\">",
"     33-37",
"    </a>",
"    ], the coagulation system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], intercellular adhesion molecule-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/40\">",
"     40",
"    </a>",
"    ], IL-4, IL-13, IL-18, interferon-gamma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/29,41,42\">",
"     29,41,42",
"    </a>",
"    ], the pro-fibrotic chemokine, CCL7 and CCL5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Involvement of the immune system in the pathogenesis of NSIP is suggested by the presence of lymphocytes in the alveolar septa and in bronchoalveolar lavage (BAL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/8,9,44,45\">",
"     8,9,44,45",
"    </a>",
"    ]. Dendritic cells (DC), which play a role in the immune response through antigen presentation, have also been noted in greater numbers in biopsies of patients with NSIP compared to UIP and were seen in close proximity to CD4 and CD8 lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibroblasts are believed to be a key effector cell in fibrotic lung diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/47\">",
"     47",
"    </a>",
"    ]. When comparing fibroblasts from patients with",
"    <span class=\"nowrap\">",
"     IPF/UIP",
"    </span>",
"    to those from patients with NSIP, differences in contractility and secretion of transforming growth factor-Beta (TGF-b) and fibronectin are observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/11\">",
"     11",
"    </a>",
"    ]. NSIP fibroblasts behave more like normal fibroblasts in these studies. These data suggest that fibroblast phenotype and other factors in the fibroblast microenvironment contribute to the fibroblast",
"    <span class=\"nowrap\">",
"     function/dysfunction",
"    </span>",
"    in IIPs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathology of NSIP is characterized by varied degrees of alveolar wall inflammation and fibrosis in a pattern that suggests temporal homogeneity (",
"    <a class=\"graphic graphic_table graphicRef81034 \" href=\"mobipreview.htm?19/8/19596\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The histopathologic features do not fit the patterns of other IIPs such as usual interstitial pneumonia (UIP), desquamative interstitial pneumonia, respiratory bronchiolitis interstitial lung disease, cryptogenic organizing pneumonia, acute interstitial pneumonia, or lymphocytic interstitial pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the histopathologic features of NSIP are well defined, the differentiation of NSIP from other IIPs, particularly",
"    <span class=\"nowrap\">",
"     IPF/UIP,",
"    </span>",
"    is difficult and even expert pathologists may disagree on a particular biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Three separate groups within NSIP have been described: Group I has primarily interstitial inflammation (",
"    <a class=\"graphic graphic_picture graphicRef75438 \" href=\"mobipreview.htm?27/22/28008\">",
"     picture 1",
"    </a>",
"    ), Group II has both inflammation and fibrosis, and Group III has primarily fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef58583 \" href=\"mobipreview.htm?43/22/44392\">",
"     picture 2",
"    </a>",
"    ). Group III is distinguished from UIP by the absence of fibroblast foci and the presence of temporal homogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classification of NSIP is further complicated by the fact that areas of both NSIP and UIP can be identified in the same patient when biopsies are taken from multiple locations. Studies evaluating patients with multiple lobe biopsies found a pattern of UIP in one lobe and NSIP in another lobe in 13 to 26 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. These mixed",
"    <span class=\"nowrap\">",
"     NSIP/UIP",
"    </span>",
"    cases had a similar prognosis to patients with",
"    <span class=\"nowrap\">",
"     IPF/UIP",
"    </span>",
"    in all lobes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of patients with suspected NSIP requires a synthesis of clinical, radiographic, and histopathologic data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In many patients with a history suspicious for NSIP, a high resolution CT scan will show characteristic findings, but surgical biopsy is usually necessary for confirmation. Once it is clear that the patient has ILD, it is important to characterize the pattern and look for clues regarding a possible etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of NSIP are dyspnea and cough that have developed subacutely over weeks to months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/8,9,45\">",
"     8,9,45",
"    </a>",
"    ]. About one-third of patients have fever or flu-like symptoms. Depending on whether an underlying collagen vascular disease is present, patients may also report dry mouth or eyes, joint or muscle pain, muscle weakness, Raynaud's phenomenon, rash, or other skin changes.",
"   </p>",
"   <p>",
"    Patients should be asked about exposure to airborne organic antigens (eg, barns, birds, hot tubs, humidifiers, mold, plastic manufacture) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/48\">",
"     48",
"    </a>",
"    ]. A complete medication list should be reviewed for medications associated with NSIP and risk factors for HIV infection should be assessed. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Drug-associated NSIP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients have bibasilar crackles, but only 10 to 35 percent have clubbing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/55\">",
"     55",
"    </a>",
"    ]. Careful attention should be paid to identifying stigmata of collagen vascular disease. Nail bed capillaroscopy may also be helpful if systemic sclerosis is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing typically demonstrates a restrictive ventilatory defect and a decrease in gas transfer manifested by a decrease in DLCO",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    desaturation during ambulatory oximetry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/48\">",
"     48",
"    </a>",
"    ]. While pulmonary function testing is not essential for making the diagnosis of NSIP, monitoring FVC and DLCO is helpful for assessing disease progression, response to therapy, and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chest imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs typically show increased interstitial markings with a basilar predominance. Patients with suspected NSIP should also undergo high resolution computed tomography (HRCT). In addition to aiding the diagnosis, serial HRCT scans may be useful to assess disease improvement or progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/57-62\">",
"     57-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent HRCT findings in NSIP include increased reticular markings, traction bronchiectasis, lobar volume loss, and ground glass opacification (GGO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/53,63\">",
"     53,63",
"    </a>",
"    ]. Although less common than the other radiographic findings, bibasilar GGO that spares the subpleural region is the most characteristic HRCT appearance; it is often associated with manifestations of fibrosis such as volume loss, reticular pattern,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    traction bronchiectasis. These changes predominantly occur in the lower lung zones. Honeycomb change is rare with NSIP; a predominance of honeycombing compared with ground glass attenuation is more suggestive of UIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. The HRCT features of idiopathic NSIP compared to connective tissue disease related NSIP are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/7-9,14,19,44,45,57-61,67-76\">",
"     7-9,14,19,44,45,57-61,67-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike",
"    <span class=\"nowrap\">",
"     IPF/UIP",
"    </span>",
"    where HRCT can at times supplant the need for a surgical lung biopsy, the ability of HRCT to make an accurate diagnosis of NSIP is more limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/77\">",
"     77",
"    </a>",
"    ]. This is in part related to variable inter reader interpretations of HRCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/78\">",
"     78",
"    </a>",
"    ]. Several series have evaluated the ability of HRCT to make a diagnosis of NSIP (as confirmed by surgical lung biopsy). The accuracy ranged from 66 to 68 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/66,71\">",
"     66,71",
"    </a>",
"    ]. Given the prognostic and treatment implications of NSIP versus",
"    <span class=\"nowrap\">",
"     IPF/UIP,",
"    </span>",
"    a surgical lung biopsy for confirmation should be strongly considered even though the HRCT suggests NSIP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some reports, bronchoalveolar lavage (BAL) shows a higher percentage of lymphocytes in patients with NSIP compared with UIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/8,9,44,45\">",
"     8,9,44,45",
"    </a>",
"    ], however, this is not always the case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/67,79\">",
"     67,79",
"    </a>",
"    ]. In addition, several other ILDs have BAL lymphocytosis so this is not specific for NSIP. Therefore, BAL cell counts cannot be utilized to differentiate NSIP from other IIPs. BAL may be helpful in excluding other causes of interstitial opacities, such as hemorrhage, infection and malignancy. As a result, BAL is not typically used for the diagnosis of ILD unless malignancy or opportunistic infection is likely, or transbronchial biopsy is being performed to obtain diagnostic tissue specimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgical lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the clinical features, radiographic appearance, and BAL are not specific for NSIP, a definitive diagnosis requires a surgical lung biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/48\">",
"     48",
"    </a>",
"    ]. This can be accomplished by thoracotomy or video assisted thoracic surgery. Ideally, samples are obtained from more than one lobe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the treatment of NSIP is to remove any inciting drugs or inhalational exposures. This alone may be adequate treatment. For patients with NSIP complicating connective tissue diseases, specific therapies for those diseases may guide treatment of the NSIP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/32/16906?source=see_link\">",
"     \"Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=see_link\">",
"     \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion will emphasize the treatment in idiopathic NSIP. A few patients, less than 20 percent, improve or stabilize without therapy; consideration of this approach should be limited to patients with mild disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/44,67\">",
"     44,67",
"    </a>",
"    ]. Patients with more severe initial disease or untreated patients who progress are treated with glucocorticoids, with or without the addition of other immunosuppressive drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/7-9,11,44,49,64,67,69,80-82\">",
"     7-9,11,44,49,64,67,69,80-82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Assessing the response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy should be assessed three to six months after its initiation, or sooner, if the patient has more severe initial disease or reports worsening symptoms. A favorable response includes a reduction in dyspnea and cough, radiographic clearing, and physiologic improvement, as assessed by forced vital capacity, total lung capacity, diffusion capacity for carbon monoxide, and both resting and exercise gas exchange. These issues are discussed in detail separately in the discussion on idiopathic pulmonary fibrosis; the principles also apply to NSIP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34762?source=see_link\">",
"     \"Treatment of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose and duration of glucocorticoid therapy is not known. Most studies of patients with idiopathic NSIP consist of a small number of patients and a variety of regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/7-9,44,49,64,67,69,80-82\">",
"     7-9,44,49,64,67,69,80-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically begin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    ideal body weight per day up to a maximum of 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one month followed by 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for an additional two months. For patients with severe disease requiring hospitalization, some authors have used pulse intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/81\">",
"     81",
"    </a>",
"    ]. The usual regimen is 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days followed by oral prednisone as dosed above. Rarely, patients need additional pulse doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who respond or stabilize with treatment, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose is gradually tapered, aiming to reach 5 to 10 mg daily or on alternate days, by the end of 12 months, with attempted cessation after at least one year of therapy. Some patients relapse when prednisone is tapered or discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/8\">",
"     8",
"    </a>",
"    ]. Such patients can be maintained for a longer period on low-dose prednisone or, if relapse occurs at higher prednisone doses, they can be treated with another immunosuppressive agent.",
"   </p>",
"   <p>",
"    Glucocorticoid treatment is associated with a variety of side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/83\">",
"     83",
"    </a>",
"    ]. Thus, there needs to be a careful and ongoing assessment of risks and benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumocystis prophylaxis is not routinely recommended for all patients taking glucocorticoids. However, in patients with underlying lung disease such as NSIP, it is reasonable to administer prophylaxis in patients on moderate to high doses of glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20 mg daily and above) since acquiring Pneumocystis could significantly worsen lung function. In addition, it is difficult to have to rule out Pneumocystis each time the patient experiences a decline in pulmonary function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other immunosuppressive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with more severe early disease, an inadequate response or intolerance to glucocorticoids, or relapsing disease have been treated with a variety of additional immunosuppressive drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/8,10,81,84\">",
"     8,10,81,84",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is generally not chosen in idiopathic NSIP because of its potential for pulmonary toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trials have assessed these therapies. All series have included concurrent glucocorticoid therapy. The choice of additional agent varies with the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) in patients who have responded to glucocorticoids but need a glucocorticoid-sparing agent, have an incomplete response, or have not responded, but are not rapidly progressing. AZA is usually started at 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and increased by 25 mg increments every 7 to 14 days up to 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, but not exceeding a maximum total dose of 200",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    most common side effects of AZA at these doses include gastrointestinal intolerance, bone marrow suppression, and infection. Divided doses may be used to decrease gastrointestinal toxicity. These and other side effects should be discussed with the patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The toxicity of AZA is predominantly related to the activity of thiopurine methyltransferase (TPMT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/85\">",
"     85",
"    </a>",
"    ]. Both genotyping and functional assays for this enzyme are now available commercially. Many clinicians perform one test or another before initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    therapy. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    has been associated with an increased risk of bacterial and opportunistic infections, but some of the increased risk may be attributable to concomitant glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/86\">",
"     86",
"    </a>",
"    ]. The role of prophylaxis for Pneumocystis in this setting has not been evaluated, but we suggest prophylaxis during combined therapy with glucocorticoid and azathioprine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have severe initial disease or have progressed despite glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , limited data from case series suggest that treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CYC) may have a beneficial effect. Some authors have used a combination of initial pulse dose glucocorticoids and cyclophosphamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the optimal dose of CYC in NSIP is unknown, the usual oral dose is 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to a maximum of 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    given as a single dose. The dose is adjusted based on the total white blood cell count, aiming to keep it above",
"    <span class=\"nowrap\">",
"     4000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34762?source=see_link\">",
"     \"Treatment of idiopathic pulmonary fibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CYC can also be given intravenously once a month to decrease the risk of bladder toxicity. In patients with normal renal function, the initial dose of intermittent intravenous CYC is usually 750",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    BSA (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/27/4529?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). In patients who are obese or elderly (eg, age greater than 70 years), the initial dose should be reduced to 500",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    of BSA. The dose should also be reduced to 500",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    BSA in the setting of renal dysfunction (especially if the estimated creatinine clearance is less than 40",
"    <span class=\"nowrap\">",
"     mL/minute).",
"    </span>",
"    Subsequent dosing is based on response to therapy and monitoring of hematologic toxicity.",
"   </p>",
"   <p>",
"    Adequate hydration should be given prior to and for 24 hours after infusion of CYC to reduce the risk of hemorrhagic cystitis. In addition, mercaptoethane sulfonate (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    ), which binds and detoxifies acrolein, is used to minimize the risk of bladder toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A trial of at least three to six months of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is needed to ensure an adequate opportunity for clinical response. Because of toxicity with long-term use, cyclophosphamide is usually discontinued after 6 to 12 months or transitioned to a less toxic agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for maintenance.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    has important hematologic, bladder, and gonadal toxicity. These should be fully discussed with the patient. CYC has also been reported to be a risk factor for Pneumocystis pneumonia, so we suggest administering prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in NSIP. In two small observational series, the addition of cyclosporine led to stabilization or clinical improvement in seven of nine patients who had not responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone and one patient who was refractory to both prednisone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/67,84\">",
"     67,84",
"    </a>",
"    ]. Until more data are available, consideration of cyclosporine is warranted only in refractory cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lung transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe NSIP that is progressive and disabling despite immunosuppressive therapy may be considered for lung transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/88\">",
"     88",
"    </a>",
"    ]. Three patients with fibrotic NSIP did well after living-donor lobar transplantation without recurrence of disease in the transplanted lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/89\">",
"     89",
"    </a>",
"    ]. The indications are similar to those for other lung diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall prognosis and response to therapy for idiopathic NSIP is favorable compared to idiopathic pulmonary",
"    <span class=\"nowrap\">",
"     fibrosis/usual",
"    </span>",
"    interstitial pneumonitis",
"    <span class=\"nowrap\">",
"     (IPF/UIP)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/44,49,53,56,64,69,73\">",
"     44,49,53,56,64,69,73",
"    </a>",
"    ]. Approximately two-thirds of treated patients with idiopathic NSIP are stable or improved in long-term follow-up, but a 15 to 26 percent mortality at five years is noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/8,44,48,64,67,81,82,90\">",
"     8,44,48,64,67,81,82,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results on serial pulmonary function testing may be a better prognostic indicator than baseline histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/56,75,91\">",
"     56,75,91",
"    </a>",
"    ]. This was suggested in a series of patients with",
"    <span class=\"nowrap\">",
"     IPF/UIP",
"    </span>",
"    (n = 61) and NSIP (n = 43) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42393/abstract/56\">",
"     56",
"    </a>",
"    ]. The patients with NSIP had longer median survival (56 versus 33 months), but this difference did not appear until after two years of follow-up. Histopathology (UIP versus NSIP) predicted prognosis as a baseline factor and at six months when changes in pulmonary physiology were examined. After 12 months of follow-up, performance on pulmonary function tests predicted subsequent mortality while histopathology was no longer predictive. Change in DLCO was the strongest determinant of mortality at 12 months of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonspecific interstitial pneumonia (NSIP) is a distinct clinical entity within the idiopathic interstitial pneumonias (IIP). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histopathologic lesion characteristic of NSIP is thickening of the alveolar septum with varying degrees of inflammatory cell opacity and fibrosis in a pattern suggesting temporal homogeneity. The fibroblast foci typical of usual interstitial pneumonia (UIP) are rarely seen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease onset is typically in the fifth or sixth decades of life, with men and women affected equally. Most patients present with the insidious onset of dyspnea and cough. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NSIP may be idiopathic or may be associated with connective tissue disease, certain drugs, human immunodeficiency virus infection, and hypersensitivity pneumonitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilateral interstitial opacities are the most typical finding on chest radiograph. High resolution computed tomography (HRCT) usually shows diffuse ground glass opacities. Volume loss, reticular pattern and traction bronchiectasis may be seen, but honeycombing is generally absent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Chest imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend histopathologic confirmation of NSIP by open or thoracoscopic lung biopsy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of NSIP has been made, every effort should be made to identify any exposure or concomitant systemic disease that is contributory. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have mild disease and minimal symptoms may be observed for a period of time without treatment. Symptoms and pulmonary function should be reassessed every three to six months and therapy is initiated if there is progression. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest initial treatment with glucocorticoids for the majority of patients with moderate to severe disease and for patients with mild disease whose symptoms have progressed or pulmonary function has declined (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The usual initial treatment is oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at 1",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      Pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      may be used for more severe disease. Additional immunosuppressive therapy is sometimes helpful for more severe disease, relapsing disease, or as a steroid sparing agent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest Pneumocystis prophylaxis for any patient with NSIP receiving moderate to high dose glucocorticoid (20 mg or more per day),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/1\">",
"      Suffredini AF, Ognibene FP, Lack EE, et al. Nonspecific interstitial pneumonitis: a common cause of pulmonary disease in the acquired immunodeficiency syndrome. Ann Intern Med 1987; 107:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/2\">",
"      Narayanswami, G, Narasimhan, M, Rosen, M, et al. Pulmonary complications of HIV disease in the era of highly active antiretroviraltherapy (HAART). Chest 2002; 122:34S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/3\">",
"      Simmons JT, Suffredini AF, Lack EE, et al. Nonspecific interstitial pneumonitis in patients with AIDS: radiologic features. AJR Am J Roentgenol 1987; 149:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/4\">",
"      Sattler F, Nichols L, Hirano L, et al. Nonspecific interstitial pneumonitis mimicking Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1997; 156:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/5\">",
"      Travis WD, Fox CH, Devaney KO, et al. Lymphoid pneumonitis in 50 adult patients infected with the human immunodeficiency virus: lymphocytic interstitial pneumonitis versus nonspecific interstitial pneumonitis. Hum Pathol 1992; 23:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/6\">",
"      Griffiths MH, Miller RF, Semple SJ. Interstitial pneumonitis in patients infected with the human immunodeficiency virus. Thorax 1995; 50:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/7\">",
"      Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/8\">",
"      Cottin V, Donsbeck AV, Revel D, et al. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998; 158:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/9\">",
"      Fujita J, Yamadori I, Suemitsu I, et al. Clinical features of non-specific interstitial pneumonia. Respir Med 1999; 93:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/10\">",
"      Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/11\">",
"      Miki H, Mio T, Nagai S, et al. Fibroblast contractility: usual interstitial pneumonia and nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2000; 162:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/12\">",
"      Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/13\">",
"      Kim DS, Yoo B, Lee JS, et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/14\">",
"      Yamadori I, Fujita J, Bandoh S, et al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sj&ouml;gren's syndrome. Rheumatol Int 2002; 22:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/15\">",
"      Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 2005; 26:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/16\">",
"      Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006; 130:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/17\">",
"      Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 2003; 123:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/18\">",
"      Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/19\">",
"      Vourlekis JS, Schwarz MI, Cool CD, et al. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am J Med 2002; 112:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/20\">",
"      Ohtani Y, Saiki S, Kitaichi M, et al. Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 2005; 60:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/21\">",
"      Pesenti S, Lauque D, Daste G, et al. Diffuse infiltrative lung disease associated with flecainide. Report of two cases. Respiration 2002; 69:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/22\">",
"      Lantuejoul S, Brambilla E, Brambilla C, Devouassoux G. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J 2002; 19:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/23\">",
"      Brinker A, Johnston M. Acute pulmonary injury in association with amiodarone. Chest 2004; 125:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/24\">",
"      Ridley MG, Wolfe CS, Mathews JA. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988; 47:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/25\">",
"      Arakawa H, Yamasaki M, Kurihara Y, et al. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging 2003; 18:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/26\">",
"      Rossi SE, Erasmus JJ, McAdams HP, et al. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000; 20:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/27\">",
"      Monaghan H, Wells AU, Colby TV, et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004; 125:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/28\">",
"      Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/29\">",
"      Ishii H, Mukae H, Kadota J, et al. Increased levels of interleukin-18 in bronchoalveolar lavage fluid of patients with idiopathic nonspecific interstitial pneumonia. Respiration 2005; 72:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/30\">",
"      Terasaki Y, Fukuda Y, Ishizaki M, Yamanaka N. Increased expression of epimorphin in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 2000; 23:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/31\">",
"      Suga M, Iyonaga K, Okamoto T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000; 162:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/32\">",
"      Kakugawa T, Mukae H, Hayashi T, et al. Expression of HSP47 in usual interstitial pneumonia and nonspecific interstitial pneumonia. Respir Res 2005; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/33\">",
"      Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/34\">",
"      Brasch F, Griese M, Tredano M, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004; 24:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/35\">",
"      Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/36\">",
"      Stevens PA, Pettenazzo A, Brasch F, et al. Nonspecific interstitial pneumonia, alveolar proteinosis, and abnormal proprotein trafficking resulting from a spontaneous mutation in the surfactant protein C gene. Pediatr Res 2005; 57:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/37\">",
"      Chibbar R, Shih F, Baga M, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod Pathol 2004; 17:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/38\">",
"      Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/39\">",
"      Kim KK, Flaherty KR, Long Q, et al. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol Med 2003; 9:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/40\">",
"      Takehara H, Tada S, Kataoka M, et al. Intercellular adhesion molecule-1 in patients with idiopathic interstitial pneumonia. Acta Med Okayama 2001; 55:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/41\">",
"      Jakubzick C, Choi ES, Kunkel SL, et al. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol 2004; 57:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/42\">",
"      Keogh KA, Limper AH. Characterization of lymphocyte populations in nonspecific interstitial pneumonia. Respir Res 2005; 6:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/43\">",
"      Choi ES, Jakubzick C, Carpenter KJ, et al. Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia. Am J Respir Crit Care Med 2004; 170:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/44\">",
"      Nagai S, Kitaichi M, Itoh H, et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/45\">",
"      Park CS, Jeon JW, Park SW, et al. Nonspecific interstitial pneumonia/fibrosis: clinical manifestations, histologic and radiologic features. Korean J Intern Med 1996; 11:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/46\">",
"      Shimizu S, Yoshinouchi T, Ohtsuki Y, et al. The appearance of S-100 protein-positive dendritic cells and the distribution of lymphocyte subsets in idiopathic nonspecific interstitial pneumonia. Respir Med 2002; 96:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/47\">",
"      Selman M, King TE, Pardo A, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/48\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/49\">",
"      Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/50\">",
"      Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004; 59:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/51\">",
"      Lettieri CJ, Veerappan GR, Parker JM, et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med 2005; 99:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/52\">",
"      Flaherty KR, King TE Jr, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004; 170:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/53\">",
"      Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008; 177:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/54\">",
"      Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 2008; 31:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/55\">",
"      Flaherty KR, Martinez FJ, Travis W, Lynch JP 3rd. Nonspecific interstitial pneumonia (NSIP). Semin Respir Crit Care Med 2001; 22:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/56\">",
"      Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/57\">",
"      Park JS, Lee KS, Kim JS, et al. Nonspecific interstitial pneumonia with fibrosis: radiographic and CT findings in seven patients. Radiology 1995; 195:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/58\">",
"      Kim EY, Lee KS, Chung MP, et al. Nonspecific interstitial pneumonia with fibrosis: serial high-resolution CT findings with functional correlation. AJR Am J Roentgenol 1999; 173:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/59\">",
"      Akira M, Inoue G, Yamamoto S, Sakatani M. Non-specific interstitial pneumonia: findings on sequential CT scans of nine patients. Thorax 2000; 55:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/60\">",
"      Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003; 123:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/61\">",
"      Nishiyama O, Kondoh Y, Taniguchi H, et al. Serial high resolution CT findings in nonspecific interstitial pneumonia/fibrosis. J Comput Assist Tomogr 2000; 24:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/62\">",
"      Akira M, Inoue Y, Arai T, et al. Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia. Thorax 2011; 66:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/63\">",
"      Silva CI, M&uuml;ller NL, Lynch DA, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 2008; 246:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/64\">",
"      Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/65\">",
"      Hunninghake GW, Lynch DA, Galvin JR, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003; 124:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/66\">",
"      Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/67\">",
"      Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/68\">",
"      Kim TS, Lee KS, Chung MP, et al. Nonspecific interstitial pneumonia with fibrosis: high-resolution CT and pathologic findings. AJR Am J Roentgenol 1998; 171:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/69\">",
"      Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/70\">",
"      Johkoh T, M&uuml;ller NL, Cartier Y, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999; 211:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/71\">",
"      Hartman TE, Swensen SJ, Hansell DM, et al. Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology 2000; 217:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/72\">",
"      MacDonald SL, Rubens MB, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001; 221:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/73\">",
"      Riha RL, Duhig EE, Clarke BE, et al. Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia. Eur Respir J 2002; 19:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/74\">",
"      Johkoh T, M&uuml;ller NL, Colby TV, et al. Nonspecific interstitial pneumonia: correlation between thin-section CT findings and pathologic subgroups in 55 patients. Radiology 2002; 225:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/75\">",
"      Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/76\">",
"      Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002; 22 Spec No:S151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/77\">",
"      Silva CI, M&uuml;ller NL, Hansell DM, et al. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 2008; 247:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/78\">",
"      Aziz ZA, Wells AU, Hansell DM, et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004; 59:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/79\">",
"      Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003; 22:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/80\">",
"      Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/81\">",
"      Kondoh Y, Taniguchi H, Yokoi T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005; 25:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/82\">",
"      Nanki N, Fujita J, Yamaji Y, et al. Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids. Intern Med 2002; 41:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/83\">",
"      Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/84\">",
"      Homma S, Sakamoto S, Kawabata M, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005; 44:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/85\">",
"      Bakker JA, Drent M, Bierau J. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. Curr Opin Pulm Med 2007; 13:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/86\">",
"      Ginzler E, Diamond H, Kaplan D, et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/87\">",
"      Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 1995; 155:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/88\">",
"      Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/89\">",
"      Date H, Tanimoto Y, Goto K, et al. A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation. Chest 2005; 128:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/90\">",
"      Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009; 33:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42393/abstract/91\">",
"      Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4306 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42393=[""].join("\n");
var outline_f41_25_42393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypersensitivity pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drug-associated NSIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chest imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgical lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Assessing the response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other immunosuppressive drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lung transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4306|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/22/28008\" title=\"picture 1\">",
"      Cellular NSIP histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/22/44392\" title=\"picture 2\">",
"      Fibrosing NSIP histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4306|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/8/19596\" title=\"table 1\">",
"      Histologic features NSIP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/27/4529?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Surface Area (Mosteller, square root method)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/49/19222?source=related_link\">",
"      Classification and clinical manifestations of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=related_link\">",
"      Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/32/16906?source=related_link\">",
"      Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_25_42394="Colorectal cancer: Epidemiology, risk factors, and protective factors";
var content_f41_25_42394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Colorectal cancer: Epidemiology, risk factors, and protective factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Dennis J Ahnen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Finlay A Macrae, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/25/42394/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/25/42394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer (CRC) is a common and lethal disease. The risk of developing CRC is influenced by both environmental and genetic factors. The epidemiology of CRC and risk factors for its development will be discussed here. Colorectal screening, clinical presentation, prognostic determinants, and treatment of colon and rectal cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=see_link\">",
"     \"Pretreatment local staging evaluation for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=see_link\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRC incidence and mortality rates vary markedly around the world. Globally, CRC is the third most commonly diagnosed cancer in males and the second in females, with over 1.2 million new cases and 608,700 deaths estimated to have occurred in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/1\">",
"     1",
"    </a>",
"    ]. Rates are substantially higher in males than in females. Global, country-specific incidence and mortality rates are available in the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the United States, both the incidence and mortality have been slowly but steadily decreasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/2\">",
"     2",
"    </a>",
"    ]. Annually approximately 142,820 new cases of large bowel cancer are diagnosed, of which 102,480 are colon and the remainder rectal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/3\">",
"     3",
"    </a>",
"    ]. Annually, approximately 50,830 Americans die of CRC, accounting for approximately 9 percent of all cancer deaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, the incidence of CRC varies over 10-fold. The highest incidence rates are in Australia and New Zealand, Europe and North America, and the lowest rates are found in Africa and South-Central Asia (",
"    <a class=\"external\" href=\"file://onlinelibrary.wiley.com/doi/10.3322/caac.20107/full\">",
"     CRC incidence by world area",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/1\">",
"     1",
"    </a>",
"    ]. These geographic differences appear to be attributable to differences in dietary and environmental exposures that are imposed upon a background of genetically determined susceptibility.",
"   </p>",
"   <p>",
"    Low socioeconomic status (SES) is also associated with an increased risk for the development of colorectal cancer; one study estimated the CRC risk to be about 30 percent increased in the lowest as compared to the highest SES quintile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/4\">",
"     4",
"    </a>",
"    ]. Unhealthy but potentially modifiable behaviors such as physical inactivity, unhealthy diet, smoking, and obesity are thought to account for a substantial proportion (estimates of one-third to one-half) of the socioeconomic disparity in risk of new onset colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Other factors, including lower rates of CRC screening, also contribute substantively to SES differences in CRC risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, CRC incidence rates have declined about 2 to 3 percent per year over the last 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/8\">",
"     8",
"    </a>",
"    ]. Incidence rates in most other western countries have been stable or increased slightly during this period. In contrast, CRC incidence rates have rapidly increased in several areas historically at low risk, including Spain, and a number of countries within Eastern Asia and Eastern Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/1,9\">",
"     1,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age is a major risk factor for sporadic CRC. Large bowel cancer is uncommon before the age of 40; the incidence begins to increase significantly between the ages of 40 and 50, and age-specific incidence rates increase in each succeeding decade thereafter (",
"    <a class=\"graphic graphic_figure graphicRef59440 \" href=\"mobipreview.htm?36/17/37151\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/10\">",
"     10",
"    </a>",
"    ]. More recent data from the United States SEER database and other Western cancer registries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/11\">",
"     11",
"    </a>",
"    ] suggest that incidence rates are increasing in the 40 to 44 age group, while they are decreasing in older groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lifetime incidence of CRC in patients at average risk is about 5 percent, with 90 percent of cases occurring after age 50. In the US, CRC incidence is about 25 percent higher in men than in women and is about 20 percent higher in African Americans than in whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/13\">",
"     13",
"    </a>",
"    ]. The incidence is higher in patients with specific inherited conditions that predispose them to the development of CRC (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A gradual shift toward right-sided or proximal colon cancers has been observed both in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and internationally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] with the greatest relative increase in incidence in cecal primaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This change in the anatomic distribution of CRCs may be, in part, related to improvements in diagnosis and treatment, and increased screening by flexible sigmoidoscopy with removal of adenomatous polyps in the descending colon, but there also appears to be a true increase in the incidence of ascending colon and cecal cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of interest, colonoscopy may be more effective in preventing left sided than right sided CRCs, which could contribute to a shift in distribution of cancers in the colon. It is likely that part of the difference is due to aspects of quality relating to the colonoscopy (poor right-sided preps, incomplete colonoscopy, anatomical configurations compromising visibility) but the biology may also differ between CRCs of the right and left colon. For example, serrated adenomas, which are flatter and more difficult to visualize endoscopically, and which characteristically carry BRAF V600E mutations and give rise to microsatellite unstable CRCs, are more common in the right colon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=see_link&amp;anchor=H15#H15\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Colonoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link&amp;anchor=H26827803#H26827803\">",
"     \"Approach to the patient with colonic polyps\", section on 'Serrated polyps'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death rates from CRC have declined progressively since the mid-1980s in the United States (",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032005.pdf\">",
"     US cancer deaths male",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032006.pdf\">",
"     US cancer deaths female",
"    </a>",
"    ) and in many other western countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/2,8,21\">",
"     2,8,21",
"    </a>",
"    ]. This improvement in outcome can be attributed, at least in part, to detection and removal of colonic polyps, detection of CRCs at an earlier stage, and more effective treatments, particularly adjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Globally, the United States has one of the highest survival rates from CRC. Data collected by the Surveillance, Epidemiology and End Results Reporting (SEER) Program of the United States National Cancer Institute suggest that 61 percent of all patients treated for CRC (all stages and sites combined) survive five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these data, mortality rates continue to increase in many countries with more limited resources and health infrastructure, particularly in Central and South America and Eastern Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some data support the view that some risk factors are more related to colon rather than to rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/23\">",
"     23",
"    </a>",
"    ], we will consider both entities together.",
"   </p>",
"   <p>",
"    Environmental and genetic factors can increase the likelihood of developing CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/24\">",
"     24",
"    </a>",
"    ]. Although inherited susceptibility results in the most striking increases in risk, the majority of CRCs are sporadic rather than familial. These risk factors can be separated into those that confer a sufficiently high risk to alter recommendations for CRC screening, and those that do not alter screening recommendations because they are thought to confer a small or uncertain magnitude of risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90629946\">",
"    <span class=\"h2\">",
"     Factors that currently influence screening recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRC screening recommendations are modified for members of hereditary colon cancer syndromes, on the basis of personal or family history of CRC or adenomas and in patients with inflammatory bowel disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90629953\">",
"    <span class=\"h3\">",
"     Hereditary CRC syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our understanding of the molecular pathogenesis of CRC (both sporadic and inherited) is evolving rapidly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings have led to the identification of several specific genetic disorders, most of which are inherited in an autosomal dominant fashion, that are associated with a very high risk of developing colon cancer. Familial adenomatous polyposis (FAP) and Lynch Syndrome (hereditary nonpolyposis colorectal cancer (HNPCC)) are the most common of the familial colon cancer syndromes, but together these two conditions account for only about 5 percent of CRC cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Familial adenomatous polyposis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial adenomatous polyposis (FAP) and its variants (Gardner's syndrome, Turcot's syndrome, and attenuated adenomatous polyposis coli) account for less than 1 percent of colorectal cancers. In typical FAP, numerous colonic adenomas appear during childhood. Symptoms appear at an average age of approximately 16 years and colonic cancer occurs in 90 percent of untreated individuals by age 45 (",
"    <a class=\"graphic graphic_picture graphicRef59413 \" href=\"mobipreview.htm?8/19/8504\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73267 \" href=\"mobipreview.htm?30/12/30917\">",
"     picture 2",
"    </a>",
"    ). An attenuated form of APC (AAPC) carries a similarly high risk of colon cancer but is characterized by fewer adenomas and an older average age of cancer diagnosis of 54 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FAP is caused by germline mutations in the adenomatous polyposis coli (APC) gene which is located on chromosome 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/25\">",
"     25",
"    </a>",
"    ]. The same gene is involved in the attenuated form of FAP, but the sites of the APC gene mutations are different [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An APC gene variant occurring in approximately 6 to 8 percent of the Ashkenazi Jewish population has been associated with a 1.5 to 2-fold increased colon cancer risk without the associated polyposis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/29\">",
"     29",
"    </a>",
"    ]. However, in itself, it does not add risk beyond that of a family history in first degree relatives and is therefore of limited clinical utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281689727\">",
"    <span class=\"h4\">",
"     MUTYH-associated polyposis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of patients with multiple colorectal adenomas (up to 500) have biallelic germline mutations in the base excision repair gene mutY homolog (MYH or MUTYH). These mutations predispose patients to autosomal recessive inheritance of multiple colonic adenomas that can present with a polyposis phenotype, frequently referred to as MUTYH-associated polyposis (MAP). The base excision repair system repairs mutations due to oxidative DNA damage. The APC gene appears to be particularly susceptible to such damage and failure of the base excision repair system often leads to somatic mutations in APC, especially G:C to T:A transversions which can lead to a polyposis phenotype. An increasing number of reports suggest that germline mutations in these MUTYH genes may account for a substantial fraction of familial CRCs that occur in the absence of a dominantly inherited familial syndrome, and that a significant number of bi-allelic carriers present with cancer without associated polyposis, making their phenotype very difficult to identify. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link&amp;anchor=H19#H19\">",
"     \"Molecular genetics of colorectal cancer\", section on 'MUTYH defects and familial CRC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Lynch syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lynch syndrome is an autosomal dominant syndrome, which is more common than FAP, and accounts for approximately 3 to 5 percent of all colonic adenocarcinomas. The name Lynch syndrome honors the pioneering work of Dr. Henry Lynch in drawing attention to the syndrome. The term Lynch syndrome is now commonly used for families who have been genetically determined to have a disease-causing defect in one of the mismatch repair genes, most commonly hMLH1, hMSH2, hMSH6, or PMS2. As a general rule, patients with Lynch syndrome have a germline mutation in one allele of a MMR gene and the second allele is inactivated in the colorectal cancers by somatic mutation, loss of heterozygosity, or epigenetic silencing by promoter hypermethylation.",
"   </p>",
"   <p>",
"    An exception is a group of families with a phenotype of loss of expression of MSH2 that is due to deletion of whole or part of the EpCAM gene which is positioned upstream of the MSH2 promotor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/30\">",
"     30",
"    </a>",
"    ]. The effect is monoallelic methylation of the MSH2 gene as a consequence of transcriptional read through due to interference with the promoter by the deletion. The phenotype appears to be epigenetic, but is in fact due to the EpCAM deletion at the DNA level. The tumor spectrum is largely restricted to the colon, as EpCAM is mostly colon specific. Endometrial cancers can occur if the deletion largely includes the 3&rsquo; portion of the EpCAM gene, close to the MSH2 promotor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term hereditary non-polyposis colorectal cancer (HNPCC) syndrome is often used to describe families who meet the Amsterdam criteria for Lynch syndrome but have either not had genetic testing or testing is uninformative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Identification of individuals with Lynch syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link&amp;anchor=H17#H17\">",
"     \"Molecular genetics of colorectal cancer\", section on 'Mismatch repair genes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The colorectal tumors that develop in patients with Lynch syndrome are characterized by early age of onset and predominance of right-sided lesions. The mean age at initial cancer diagnosis is 48 years, with some patients presenting in their 20s. Nearly 70 percent of first lesions arise proximal to the splenic flexure, and approximately 10 percent will have synchronous (simultaneous onset of two or more distinct tumors separated by normal bowel) or metachronous cancers (non-anastomotic new tumors developing at least six months after the initial diagnosis). The chance of developing metachronous colorectal cancer in those who have segmental resections only is high; in a recent study of 382 gene carriers, 16 percent at 10 years, rising to 62 percent at 30 years after primary resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extracolonic cancers are very common in Lynch syndrome, particularly endometrial carcinoma, which may occur in up to 60 percent of female mutation carriers in some families. Other sites at increased risk of neoplasm formation include the ovary, stomach, small bowel, hepatobiliary system, brain and renal pelvis or ureter, and possibly breast and prostate.",
"   </p>",
"   <p>",
"    Penetrance estimates for colon and endometrial cancer in carriers of MLH1 or MSH2 mutations were initially thought to be &gt;80 percent, and 40 percent, respectively. However, these early estimates were based on selected families referred for gene testing, which produced biased estimates (upwards). More recent estimates from population-based series suggest that penetrance estimates are about one-half of what they were initially, and indicates that much of the risk attributed to this syndrome is over by the mid fifties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Personal or family history of sporadic CRCs or adenomatous polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a personal history of CRC or adenomatous polyps of the colon are at risk for the future development of colon cancer. In patients undergoing resection of a single CRC, metachronous primary cancers develop in 1.5 to 3 percent of patients in the first five years postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A personal history of large (&gt;1 cm) adenomatous polyps and polyps with villous or tubulovillous histology also increase the risk of CRC, particularly if multiple [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/34\">",
"     34",
"    </a>",
"    ]. The relative risk ranges from approximately 3.5 to 6.5 in such patients. On the other hand, as a group, patients with one or two small (&lt;1 cm) tubular adenomas do not appear to be at substantially increased risk of metachronous CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family history is also an important risk factor even outside of the syndromes with a defined genetic predisposition. Having a single affected first-degree relative (parent, sibling, or child) with colorectal cancer increases the risk about twofold over that of the general population. Risk is further increased if two first-degree relatives have colon cancer or if the index case is diagnosed below 50 to 60 years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link&amp;anchor=H13#H13\">",
"     \"Molecular genetics of colorectal cancer\", section on 'APC gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is commonly believed that patients who have a family member with an adenomatous colonic polyp may also be at increased risk for adenoma or colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], and guidelines recommend early-onset screening (age 40 years) for people with a family history of polyps in relatives &lt;60 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/38\">",
"     38",
"    </a>",
"    ]. These recommendations were largely based on studies that used self-reported family history information from individuals with and without adenomas rather than systematic colonoscopy in relatives of patients with and without colorectal cancer which would be a better design. The magnitude of risk may be overestimated because of increased efforts to look for cancer in families who already have a history of colorectal neoplasia. Also, family history for colonic polyps may be inaccurate. In one study, the positive predictive value for self-reported polyp was 80.9 percent, and the negative predictive value was 85.8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of whether having a first-degree relative with colorectal polyps increases the risk of colorectal cancer noted that while multiple case-control studies have identified an increased risk of adenomas when family members have an adenoma, only two studies were found that directly addressed whether a family history of adenoma increases risk for colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/38\">",
"     38",
"    </a>",
"    ]. Both studies reported an increased risk, but both had limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/37,40\">",
"     37,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cross sectional study of 6139 adults undergoing employer-sponsored CRC screening with colonoscopy used data from a preprocedure questionnaire that asked whether any first-degree relatives had CRC or adenomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/40\">",
"       40",
"      </a>",
"      ]. The risk of CRC was significantly greater in persons who had first-degree relatives with adenomas compared to those who did not (2.3 versus 0.5 percent, relative risk [RR] 4.36 (95% CI 1.60-10.21)). The study was limited by its restriction to Japanese patients and the lack of verification of the questionnaire answers.",
"     </li>",
"     <li>",
"      In the second study, the first degree relatives of 306 French individuals with large adenomas (&ge;1 cm) were offered screening colonoscopy; the 168 individuals (55 percent of the total) who agreed to be screened or had a recent colonoscopy were matched (age, sex, geographic location) with two individuals from a control group, which was selected from 1362 consecutive persons undergoing colonoscopy for minor symptoms who had neither a personal or family history of CRC or adenomas.",
"      <br/>",
"      <br/>",
"      Either CRC or large adenomas (&ge;1 cm) were found in a significantly greater number of persons who had first-degree relatives with large adenomas compared to those without such a history (14 of 168 versus 13 of 307 [8.3 versus 4.2 percent], adjusted odds ratio [OR] 2.27, 95% CI 1.01-5.09). However, for CRC alone, the difference in risk was not statistically significant (3 versus 1 percent, OR 3.90, 95% CI 0.89-17.10). Furthermore, the study inadvertently included persons who had first-degree relatives with CRC in the large adenoma study group, which would have made the risk factor seem more important than it actually was. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    US recommendations from the American College of Gastroenterology, Multisociety Task Force on Colorectal Cancer from the American Cancer Society, and the American College of Radiology as well as the World Gastroenterology Organisation all suggest early institution of colonoscopic surveillance in individuals who have a first-degree relative with an adenoma diagnosed under the age of 60, beginning at age 40, or 10 years earlier than the youngest cancer in the family, particularly (and in some countries, only) if there are multiple first degree relatives with colorectal cancer,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an age of onset of colorectal cancer in the family at 60 (50 or 55 in some countries) years or younger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Guidelines in other countries (eg, Canada) do not recommend screening of relatives with adenomas, apart from the multiple polyposis syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\", section on 'Family history of colonic polyps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence on risk for relatives of adenoma patients includes studies with flawed design and is still maturing. In countries where screening is recommended for relatives of adenoma patients, we suggest that patients whose only familial risk factor for colorectal cancer is a relative with a history of adenomatous polyp that is not clearly documented as an advanced adenoma (&ge;1 cm, or high-grade dysplasia or villous elements) be screened as an average-risk patient, with screening options presented (",
"    <a class=\"graphic graphic_table graphicRef62904 \" href=\"mobipreview.htm?23/8/23693\">",
"     table 1",
"    </a>",
"    ). Individuals who have a first-degree relative with a documented history of advanced adenoma should be screened similarly to those with a family history of colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inflammatory bowel disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16092481\">",
"    <span class=\"h4\">",
"     Ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a well documented association between chronic ulcerative colitis and colonic neoplasia, with the extent, duration, and activity of disease being the primary determinants. Pancolitis confers a 5- to 15-fold increase in risk compared to the expected incidence in the general population, while disease that is limited to the left side of the colon is associated with about a threefold relative risk; in comparison, the risk does not appear to be significantly increased with proctitis or proctosigmoiditis alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/45\">",
"     45",
"    </a>",
"    ]. There is evidence that some treatments for inflammatory colitis may decrease CRC risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22090?source=see_link&amp;anchor=H110256055#H110256055\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Colorectal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reasonable estimate of the colon cancer incidence is about 0.5 percent per year for subjects with disease duration between 10 and 20 years, then 1 percent per year thereafter. Most reports suggest that the co-occurrence of ulcerative colitis and primary sclerosing cholangitis identifies a subset of patients with an even greater risk. Others have identified the presence of pseudopolyps as an independent risk factor, particularly if large and complex. Strictures should always raise a suspicion of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link&amp;anchor=H3#H3\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Ulcerative colitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40342?source=see_link\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the patient with colonic polyps\", section on 'Inflammatory pseudopolyps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in risk of colon cancer begins about 8 to 10 years after the initial diagnosis of pancolitis, and at 15 to 20 years for colitis limited to the left colon (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63411 \" href=\"mobipreview.htm?9/60/10191\">",
"     image 1",
"    </a>",
"    ). The probability of developing cancer then increases with disease duration, and by the fourth decade of disease it reaches as high as 30 percent in patients with pancolitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link&amp;anchor=H4#H4\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Pancolitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16092488\">",
"    <span class=\"h4\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are much less data, it appears that pancolitis due to Crohn's disease is associated with a similar relative risk of colon malignancy as extensive ulcerative colitis, although the data are less consistent. Recommendations from expert groups vary for Crohn's disease where there is less colonic involvement, but most guidelines recommend surveillance when one-third or more of the colonic mucosa is involved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link&amp;anchor=H31#H31\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Crohn's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15837087\">",
"    <span class=\"h3\">",
"     Abdominal radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult survivors of childhood malignancy who received abdominal radiation are at significantly-increased risk of subsequent gastrointestinal neoplasms, the majority being colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Guidelines from the Children&rsquo;s Oncology Group recommend colonoscopy every five years for survivors of childhood cancer who received 30 Gy or more of abdominal radiation, with screening beginning 10 years after radiation or at age 35 years, whichever is later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link&amp;anchor=H8#H8\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Other significant risks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A history of radiation therapy for prostate cancer was associated with an increased risk of rectal cancer in a large database study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/49\">",
"     49",
"    </a>",
"    ]. The magnitude of risk was similar to that observed in patients with a family history of colonic adenomas. Whether such cancers follow an adenoma to cancer sequence, and whether increased screening in such patients would improve cancer detection rates and outcomes, is unclear. In contrast to adult survivors of childhood cancer, increased surveillance is not currently recommended in this group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265276647\">",
"    <span class=\"h2\">",
"     Factors that may influence screening recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90630106\">",
"    <span class=\"h3\">",
"     Race/ethnicity and gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;African Americans have the highest CRC rates of all ethnic groups in the US.",
"    <strong>",
"    </strong>",
"    CRC mortality is about 20 percent higher in African Americans than it is in whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, CRCs occur at a younger age and there is a higher frequency of CRC under age 50 in African Americans. There also appears to be a more proximal distribution of both CRCs and adenomas in African Americans.",
"   </p>",
"   <p>",
"    Both the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy recommend that CRC screening begin at age 45 in African Americans and that colonoscopy is the preferred screening test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/41,50\">",
"     41,50",
"    </a>",
"    ]. However, other US national guidelines, including the US Preventive Services Task Force and the Multisociety Task Force do not recommend that screening be altered as a function of",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. This subject is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link&amp;anchor=H8#H8\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Other significant risks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRC mortality is about 25 percent higher in men than in women, and both colonic adenomas and CRCs appear to have a more proximal distribution in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/53\">",
"     53",
"    </a>",
"    ], particularly in postmenopausal women. None of the major US organizations recommend that screening be stratified by gender, but some authors have argued that this should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/54\">",
"     54",
"    </a>",
"    ],or that flexible sigmoidoscopy is an inadequate screening test in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265276695\">",
"    <span class=\"h3\">",
"     Acromegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports suggest that colonic adenomas and CRC both occur with increased frequency in acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], particularly in those with uncontrolled disease. Patients with acromegaly are more likely to have multiple adenomatous polyps, and the polyps are more likely to be proximal to the splenic flexure (and therefore, less likely to be reached by the sigmoidoscope).",
"   </p>",
"   <p>",
"    Guidelines from the Acromegaly Consensus Group recommend colonoscopy for early detection and treatment of premalignant colonic polyps at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30776?source=see_link&amp;anchor=H15#H15\">",
"     \"Causes and clinical manifestations of acromegaly\", section on 'Colonic effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265276753\">",
"    <span class=\"h3\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplantation, in association with long-term immunosuppression, has been linked with increased colorectal cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In general, cancer rates in kidney transplant recipients are similar to those of non-transplanted individuals 20 to 30 years older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .) At some institutions (including that of one of the authors), renal transplant recipients are screened for colorectal cancer starting at age 40 or five years after transplant, whichever is first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90630250\">",
"    <span class=\"h2\">",
"     Risk factors that do not alter screening recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a large number of clinical environmental and lifestyle factors that are associated with a small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uncertain increased risk of CRC. Although many of these associations have been seen consistently in observational studies, the causal relationship of these associations is largely unproven. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diabetes mellitus and insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing evidence suggests that diabetes mellitus is associated with an elevated risk of CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/60-68\">",
"     60-68",
"    </a>",
"    ]. A meta-analysis of 14 studies (six case-control and eight cohort) estimated that the risk of colon cancer among diabetics was approximately 38 percent higher than nondiabetics (RR 1.38, 95% CI 1.26-1.51), and for rectal cancer, it was 20 percent higher (RR 1.20, 95% CI 1.09-1.31) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/67\">",
"     67",
"    </a>",
"    ]. The associations remained when the analysis was limited to studies that controlled for smoking, obesity, and physical activity. This level of increased risk is insufficient to influence surveillance recommendations based upon other factors such as age.",
"   </p>",
"   <p>",
"    One possible explanation linking diabetes to CRC is hyperinsulinemia, because insulin is an important growth factor for colonic mucosal cells and stimulates colonic tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Plasma concentrations of insulin-like growth factor (IGF-I) and IGF binding protein-3 (IGFBP-3) were reported to influence the risk of CRC in a cohort of 14,916 men who were followed prospectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/72\">",
"     72",
"    </a>",
"    ]. Subjects with values of IGF-I in the highest quintiles were more likely to develop CRC compared to those with values in the lowest quintiles (relative risk 2.51); in contrast, increased plasma concentrations of IGFBP-3 were protective (relative risk 0.28). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=see_link\">",
"     \"Dietary carbohydrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar relationship between serum levels of C-peptide (an indicator of insulin production) and CRC risk was reported in a cohort of individuals followed in the Physicians' Health Study, independent of IGF-I or IGFBP-3 levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic insulin therapy may also be associated with an increased risk of CRC in diabetics, although the data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to increasing risk of the disease, diabetes may also influence prognosis among patients with CRC. In one cohort study of patients with non-metastatic CRC who were enrolled in the Cancer Prevention Study-II Nutrition Cohort, individuals with type 2 diabetes mellitus had a significantly higher risk of cancer-specific mortality relative to those without diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/76\">",
"     76",
"    </a>",
"    ]. The association was not related to insulin levels as use of insulin did not influence CRC mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19181667\">",
"    <span class=\"h3\">",
"     Use of androgen deprivation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 107,859 men aged 67 and older with prostate cancer who were included in the linked",
"    <span class=\"nowrap\">",
"     SEER/Medicare",
"    </span>",
"    database suggests that long-term androgen deprivation therapy (ADT) may also increase the risk of CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/77\">",
"     77",
"    </a>",
"    ]. Men who received treatment with a gonadotropin-releasing hormone (GnRH) agonist or orchidectomy had a higher risk of developing CRC, and the risk increased with longer duration of ADT. Compared with no ADT, the hazard ratio (HR) for CRC associated with a GnRH agonist for 25 months or longer was 1.31 (95% CI 1.12 to 1.53), and for orchidectomy, it was 1.37 (95% CI 1.14 to 1.66). The mechanism(s) underlying this putative association are unclear, but insulin resistance as a consequence of ADT has been suggested as a possible contributor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/78\">",
"     78",
"    </a>",
"    ]. These risk estimates fall below those qualifying for special attention in most screening guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relationship between cholecystectomy and right-sided colon cancer has been described in some reports. As an example, in a study of 278,460 patients followed for up to 33 years after surgery, patients who had undergone cholecystectomy had a slightly increased risk of right-sided colon cancer (standardized incidence ratio 1.16), but not more distal colon cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/79\">",
"     79",
"    </a>",
"    ]. Several meta-analyses have confirmed this association with proximal colon cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], although discordant data have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The mechanism is thought to be related to alterations in bile acid composition in the colon after cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between alcohol consumption and an increased risk of CRC has been observed in several studies. A meta-analysis of 27 cohort and 34 case-control studies concluded that, compared to never drinkers, there was a significant increase in risk of CRC for moderate (two to three drinks per day, summary relative risk [RR] 1.21, 95% CI 1.13-1.28) and heavy drinkers (&ge;4 drinks per day, RR 1.52, 95% CI 1.27-1.81) but not light drinkers (&le;1 drink per day, RR 1.00, 95% CI 0.95-1.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/87\">",
"     87",
"    </a>",
"    ]. These results are consistent with prior pooled analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. However, in contrast to prior studies, a dose-response analysis found a significant 7 percent increase in risk of CRC even in light drinkers (RRs for ingestion of 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of ethanol 1.07 [95% CI 1.04-1.10]). The elevated risk may be related to interference of folate absorption by alcohol and decreased folate intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link\">",
"     \"Overview of the risks and benefits of alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large prospective cohort studies have shown that being obese confers an approximately 1.5-fold increased risk of developing CRC relative to being normal weight (body mass index 18.5 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. One systematic review of data from 29 studies totaling 37,334 patients reported that each 5",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    increase in body mass index (BMI) was associated with a 24 percent increased incidence of both colon and rectal cancer in men, and a 9 percent higher incidence of colon cancer in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, obesity also increases the likelihood of dying from CRC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H28#H28\">",
"     \"Health hazards associated with obesity in adults\", section on 'Cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H40#H40\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Diet and exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other risk factors have been studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of coronary heart disease has been associated with an increased risk of CRC and advanced adenomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/95\">",
"       95",
"      </a>",
"      ]. The mechanisms underlying the association are unclear but may be related to shared risk factors.",
"     </li>",
"     <li>",
"      Cigarette smoking has been associated with increased incidence and mortality from CRC. A meta-analysis of 106 observational studies estimated that the risk of developing CRC was increased among cigarette smokers compared to those who never smoked (RR 1.18, 95% CI 1.11-1.25) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/96\">",
"       96",
"      </a>",
"      ]. The risk of dying from CRC was also increased among smokers (RR 1.25, 95% CI 1.14-1.37). For both incidence and mortality, the association was stronger for cancer of the rectum than the colon.",
"      <br/>",
"      <br/>",
"      Cigarette smoking is also a risk factor for essentially all types of colonic polyps. For adenomatous polyps, the risk is particularly high for more advanced adenomas (ie, larger and with dysplastic features) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/97\">",
"       97",
"      </a>",
"      ]. Smoking is also a major risk factor for serrated polyps of the colon including those that are hyperplastic and those that are adenomatous [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/98,99\">",
"       98,99",
"      </a>",
"      ]. In addition, smoking may increase for the risk of CRC in patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ureterocolic anastomoses after extensive bladder surgery are associated with an increased risk of neoplasia in close proximity to the ureteric stoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/101\">",
"       101",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/34/32298?source=see_link&amp;anchor=H26#H26\">",
"       \"Urinary diversion and reconstruction following cystectomy\", section on 'Other'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the data are not entirely consistent, long-term consumption of red meat or processed meats may be associated with an increased risk of CRC, particularly left sided tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/102-106\">",
"       102-106",
"      </a>",
"      ]. High temperature cooking (eg, barbecuing) has been implicated, probably through the production of polyaromatic hydrocarbons and other carcinogens produced from proteins in the charring process. Lean red meat may be associated with less risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/107\">",
"       107",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The excess risk associated with red meat consumption is counterbalanced by a variety of potential benefits such as repletion of iron and vitamin B12.",
"     </li>",
"     <li>",
"      The evidence linking caffeine (coffee, tea) consumption and CRC is inconsistent. Although a link between high rates of coffee consumption and a reduced risk of CRC was reported in a meta-analysis of 12 cases-control studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/108\">",
"       108",
"      </a>",
"      ] and an analysis from the NIH-AARP Diet and Health Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/109\">",
"       109",
"      </a>",
"      ] data from the Nurses Health Study, the Health Professionals Follow-Up Study, and a pooled analysis of data from 13 prospective cohort studies do not support this finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/110,111\">",
"       110,111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The biologic relationship between inherited BRCA gene mutations and CRC is unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/112\">",
"       112",
"      </a>",
"      ]. Although some studies derived from a cancer risk clinic and the Breast Cancer Linkage Consortium have reported an approximately twofold increased risk of colon cancer among BRCA1 mutation carriers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/113,114\">",
"       113,114",
"      </a>",
"      ], other population-based series have not confirmed such an association [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/115,116\">",
"       115,116",
"      </a>",
"      ]. If there is an increased risk, it is likely to be small",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      limited to certain groups of carriers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An association of colon cancer with Barrett's esophagus has been reported although the data are conflicting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/117-123\">",
"       117-123",
"      </a>",
"      ]. If real, it is tempting to suggest that obesity may be the pathophysiologic link [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several bacterial and viral agents (eg, Streptococcus bovis (S. bovis), H. pylori, JC virus, human papilloma virus [HPV], and most recently Fusobacterium) have been proposed as risk factors for CRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/124-127\">",
"       124-127",
"      </a>",
"      ]. The data on H pylori, JC virus, and HPV have been mixed and inconclusive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/124\">",
"       124",
"      </a>",
"      ]. The association between infection with S. bovis, particularly the streptococcus gallolyticus subtype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/128\">",
"       128",
"      </a>",
"      ], and colonic neoplasia is well described but is thought to be a consequence of rather than a risk factor for colonic neoplasia and discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22041?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22041?source=see_link&amp;anchor=H24506924#H24506924\">",
"       \"Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection\", section on 'Association with colonic neoplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some, but not all, reports have indicated a significant increase in the incidence of colorectal neoplasia in HIV-positive patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/129,130\">",
"       129,130",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=see_link&amp;anchor=H1560506431#H1560506431\">",
"       \"HIV infection and malignancy: Management considerations\", section on 'Colorectal cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior treatment for Hodgkin lymphoma has been associated with an increased risk of CRC in epidemiologic studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672665#H1167672665\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Screening for colorectal cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROTECTIVE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of factors have been reported by at least some studies to be associated with a decreased risk of CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/131\">",
"     131",
"    </a>",
"    ]. These include regular physical activity, a variety of dietary factors, the regular use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or nonsteroidal antiinflammatory drugs (NSAIDs), and hormone replacement therapy in postmenopausal women. None of these factors are currently used to stratify CRC screening recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90630437\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial observational data suggest that regular physical activity, either occupational or leisure time, appears to be associated with protection from colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. In a meta-analysis of 21 studies, there was a significant 27 percent reduced risk of proximal colon cancer when comparing the most versus the least active individuals (relative risk [RR] 0.73, 95% CI 0.66-0.81) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/133\">",
"     133",
"    </a>",
"    ] and a 26 percent reduction for distal colon cancer (RR 0.74, 95% CI 0.68-0.80). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the benefits and risks of exercise\", section on 'Cancer prevention and treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism underlying the apparent protective association of physical activity is not known and no intervention trials of physical activity for CRC prevention have been reported. It is not known whether weight loss alone in the absence of increased physical activity would decrease CRC risk in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many epidemiologic studies have shown an association between the intake of a diet high in fruits and vegetables and protection from colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/134-136\">",
"     134-136",
"    </a>",
"    ]. The relative risk of colorectal cancer is approximately 0.5 comparing groups with the highest intake to those with the lowest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/136\">",
"     136",
"    </a>",
"    ]. However, discordant data have also been published. The link between consumption of produce and colorectal cancer was challenged in a prospective study that combined subjects from the Nurses' Health Study (88,764 women) and the Health Professionals' Follow-up Study (47,325 men) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/137\">",
"     137",
"    </a>",
"    ]. There was no significant association between the consumption of fruits, vegetables, or fruits and vegetables on the incidence of either colon or rectal cancer, independent of vitamin supplement use or smoking habits.",
"   </p>",
"   <p>",
"    A pooled analysis of fourteen cohort studies, including the previous study, concluded that eating more than 800 g fruit and vegetables daily, compared to less than 200 g, decreased risk for distal (RR 0.74) but not for proximal colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/138\">",
"     138",
"    </a>",
"    ]. On the other hand, a later meta-analysis of 19 cohort studies concluded that there was a weak protective effect of fruit and vegetable intake for highest versus lowest intake of fruits and vegetables (RR 0.92, 95% CI 0.86-0.99) and that the inverse association appeared limited to distal colon cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/139\">",
"     139",
"    </a>",
"    ]. Most of the risk reduction was attributable to increasing intake above a threshold value of 100",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    with relatively little benefit associated with higher levels of intake. As a reference, a typical apple weighs &gt;200 g. These data suggest that there might be little benefit to increasing the consumption of fruits and vegetables beyond the levels associated with eating a reasonable balanced diet.",
"   </p>",
"   <p>",
"    Some reports suggest that a diet low in red meat, animal fat",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholesterol may also be protective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/102,140-142\">",
"     102,140-142",
"    </a>",
"    ]. As an example, in a study of nearly 10,000 men and women, subjects in the highest quartile of cholesterol consumption had a significantly higher risk of colorectal cancer compared to the lowest quartile (RR 3.26), even after adjusting for fruit and vegetable consumption and other relevant factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of laboratory, nutritional, and epidemiologic studies have identified a role for dietary fiber in the pathogenesis of CRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/143\">",
"     143",
"    </a>",
"    ]. However, the degree to which dietary fiber protects against the development of adenomas or CRC is uncertain since the results of epidemiologic studies and at least two randomized trials are discordant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decreased risk of colonic adenomas and CRC with higher intake of fiber was observed in four large epidemiologic studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/144-147\">",
"       144-147",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, in the Nurses' Health study, no relationship was noted between fiber intake and the risk of CRC or adenomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/148\">",
"       148",
"      </a>",
"      ]. Similarly, the Women's Health Initiative Trial found no protective effect of a modest low fat, increased fiber and increased fruit and vegetable dietary intervention on CRC incidence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pooled analysis of 13 prospective cohort studies (involving 725,628 men and women followed for 6 to 20 years) found that dietary fiber intake was inversely associated with the risk of CRC but the association was no longer apparent after accounting for other dietary risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/150\">",
"       150",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a meta-analysis funded by the World Cancer Research Fund found that for every 10",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      increase in dietary fiber consumption, there was a significant reduction in the risk of colorectal cancer by 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/151,152\">",
"       151,152",
"      </a>",
"      ]. There was a difference between different food groups. While fiber from grains was associated with protection from CRC, fruit, vegetable and legume-based fiber was not.",
"     </li>",
"     <li>",
"      In two randomized controlled studies from the United States as well as one from Australia, fiber supplementation had no significant protective effect for the development of total colorectal adenomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/107,153,154\">",
"       107,153,154",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of five studies involving a total of 4349 patients concluded that there was no definitive evidence that increased dietary fiber reduces the incidence or recurrence of adenomatous polyps within a two- to four-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/155\">",
"       155",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While multiple potential explanations may account for the differences among studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/147,156\">",
"     147,156",
"    </a>",
"    ], the type of fiber may be one important factor, as was found in the World Cancer Research Fund meta-analysis. In addition to this analysis, the Australian trial described above, which showed a significant reduction in advanced adenomas (only), used unprocessed wheat bran, which may be more effective in delivering the benefits of cereal fiber as compared with more processed forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/107\">",
"     107",
"    </a>",
"    ]. Ultimately, the degree of protection from dietary fiber, if any, will likely remain unsettled in the absence of prospective intervention studies.",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for the impact of dietary fiber on colon cancer occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/157\">",
"     157",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Resistant starch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant starch refers to those forms of starch which escape digestion in the small bowel and pass to the colon, where they are fermented with the production of short-chain fatty acids. Butyrate, one of these fatty acids, has antineoplastic properties in the colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/158\">",
"     158",
"    </a>",
"    ]. While this led to initial enthusiasm as to the potential of resistant starch as a chemopreventive agent, a randomized trial of resistant starch (Novelose, 30 g daily) failed to show a beneficial impact on adenoma or cancer development in individuals with hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/159,160\">",
"     159,160",
"    </a>",
"    ]. Additional trials of other forms of resistant starch that are capable of delivering higher levels of butyrate to the colon are in progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Folic acid and folate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate is the natural form of the vitamin occurring in food and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is the synthetic form used in food fortification and supplements. Based upon biochemical pathways, the two may not be equivalent and have different in vitro effects.",
"   </p>",
"   <p>",
"    Data from animal and human studies have demonstrated that folate inhibits pathogenesis of cancer in a number of tissues including the colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/161\">",
"     161",
"    </a>",
"    ]. However, whether folate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    have a role in prevention of colorectal cancer is unclear. By contrast, the possibility that folic acid supplementation",
"    <strong>",
"     increases",
"    </strong>",
"    the risk of colon cancer has also been raised. The following represents the available data on folate and colorectal cancer risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined analysis of data from two large cohorts from the Nurses' Health Study and the Health Professionals Follow-up Study provide observational evidence in support of a protective effect from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/162\">",
"       162",
"      </a>",
"      ]. There was an association between total folate intake 12 to 16 years before diagnosis and a lower risk of colorectal cancer (RR: 0.69; 95% CI 0.51 to 0.94 for &ge;800 compared with &lt;250 micrograms of folate per day), but no association with intake in the more recent past. In contrast, both long- and short-term intake of total folate was associated with a lower risk of colorectal adenoma, with a strong association with intake four to eight years before diagnosis (OR 0.68; 95% CI: 0.60 to 0.78 for &ge;800 compared with &lt;250 micrograms of folate per day). These observational data suggest that folic acid supplementation could be beneficial in the pre-adenoma stage but not beyond.",
"     </li>",
"     <li>",
"      Others have suggested that the protective effect of folates might be limited to dietary (food) rather than supplemental intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/163\">",
"       163",
"      </a>",
"      ]. The protective effect may also depend upon an individual's particular genotype for methylenetetrahydrofolate reductase, an enzyme involved in folate metabolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/164\">",
"       164",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to these data, at least two controlled trials involving patients with colonic adenomas found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation did not reduce the risk of recurrent adenomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/165,166\">",
"       165,166",
"      </a>",
"      ]. Furthermore, in one of the trials, supplementation was associated with an increased risk of having three or more adenomas and of noncolorectal cancers, raising the possibility that folic acid supplementation in adults could be detrimental rather than beneficial for adenoma formation, particularly in those who already have a propensity to form colonic neoplasms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/165\">",
"       165",
"      </a>",
"      ]. In support of this possibility are population-based studies that have correlated a small increase in the incidence of colon cancer concurrent with the fortification of the United States food supply with folic acid for prevention of neural tube defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/167\">",
"       167",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      On the other hand, a study of 99,523 US participants enrolled in the Cancer Prevention Study II Nutrition cohort that examined the association between folate intake (dietary or supplemental) and colorectal cancer risk failed to document an increased risk of colorectal cancer from high folate intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/168\">",
"       168",
"      </a>",
"      ]. These data are consistent with the findings from the Nurses' Health Study and the Health Professionals Follow-up Study described above and should help to allay concerns about a possible strong procarcinogenic role of folate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/139\">",
"       139",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Vitamin B6 (pyridoxine)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data suggest a modest association between higher vitamin B6 (pyridoxine) intake and decreased colorectal cancer risk. In a meta-analysis of prospective studies, the pooled relative risks (RR) of colorectal cancer for the highest versus lowest categories of vitamin B6 intake and of blood levels of pyridoxal 5'-phosphate (the active form of vitamin B6) were 0.90 (95% CI 0.75 to 1.07) and 0.52 (95% CI 0.38 to 0.71), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/169\">",
"     169",
"    </a>",
"    ]. Omitting one study that contributed substantially to heterogeneity in the studies of vitamin B6 intake, the protective effect of highest versus lowest vitamin B6 intake on colorectal cancer risk was statistically significant (pooled RR 0.80, 95% CI 0.69 to 0.92).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Calcium and dairy products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another possible protective factor is increased intake of dietary or supplemental calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/170-177\">",
"     170-177",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined analysis of the Nurses' Health Study (n = 87,998 women) and the Health Professionals' Follow-up Study (n = 47,344 men) found that higher calcium intake (&gt;1250 mg daily versus &le;500 mg daily) was associated with a significant reduction in the risk of distal colon cancers (relative risk [RR] 0.65, 95 percent confidence interval [CI] 0.43 to 0.98) but not proximal cancers (RR 1.14, 95% C, 0.72-1.81) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/174\">",
"       174",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar degree of benefit was noted in a pooled analysis of individual data on 534,536 individuals from 10 cohort studies that assessed dietary intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/176\">",
"       176",
"      </a>",
"      ]. The RR for CRC in the highest as compared to the lowest quartile of calcium intake was 0.86 (95% CI 0.78-0.95). Compared to the lowest category of milk intake (&lt;70",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      individuals ingesting &ge;250",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      had a comparable reduction in the risk of CRC (RR 0.85, 95% CI 0.78-0.94).",
"     </li>",
"     <li>",
"      The National Institutes of Health-AARP study (which included 293,907 men and 198,903 women ages 50 to 71 followed for an average of seven years) concluded that dietary calcium significantly lowered the risk of digestive cancers, particularly colorectal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/177\">",
"       177",
"      </a>",
"      ]. The risk decreased up to approximately 1300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      above which no further reduction was observed. Among those with the highest quintile of calcium intake, the risk of colorectal cancer was decreased by approximately 16 percent (hazard ratio [HR] 0.84, 95% CI 0.77-0.92), almost identical results to the pooled analysis described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/176\">",
"       176",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least three controlled trials have evaluated the efficacy of calcium supplementation in prevention of recurrence of colorectal adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/178\">",
"     178",
"    </a>",
"    ]. A meta-analysis of these data (including a total of 1485 subject) concluded that the risk of recurrence was significantly lower in patients randomized to calcium (RR 0.80, 95% CI 0.68-0.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these benefits in adenoma prevention trials, whether calcium supplementation reduces the risk of colorectal cancer is unproven. The only large controlled trial to evaluate this issue included 36,282 post-menopausal women who were randomly assigned to the combination of calcium plus vitamin D or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/179\">",
"     179",
"    </a>",
"    ]. No significant difference in the rate of invasive colorectal cancer was observed during a mean follow-up of seven years. Questions have been raised as to whether the doses of calcium and vitamin that were used in the trial were sufficient to prevent colon cancer. The study is continuing to determine whether a benefit might be observed with longer follow-up.",
"   </p>",
"   <p>",
"    Other data suggest that the protective effect of calcium may depend upon an individual's genotype for the vitamin D receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/175\">",
"     175",
"    </a>",
"    ]. A controlled trial suggested that calcium supplementation was beneficial only in patients with normal vitamin D levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium supplementation has been recommended for the primary or secondary prevention of colonic adenomas by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/173\">",
"     173",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemiologic studies of dairy products and CRC risk have provided mixed results, with some studies reporting inverse associations between intake of total dairy products, milk,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    yogurt and CRC risk, and others finding no association. Dairy products have been hypothesized to protect against CRC because of their high calcium content; however, some dairy products, such as cheese and cream, have a high fat content, which may counterbalance the protective effect, possibly by affecting the bile acid composition in the colon. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Cholecystectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A meta-analysis of 19 cohort studies concluded that diets with higher milk and total dairy product intake were associated with a significant, but modest, reduction in CRC risk (summary RR for milk 0.82, 95% CI 0.74-0.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/181\">",
"     181",
"    </a>",
"    ]. The protective effect was restricted to colon and not rectal cancer. There was no association between intake of cheese or other dairy products (including low-fat dairy products) and CRC risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4999625\">",
"    <span class=\"h3\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D and its metabolites act as inhibitors of colorectal cancer progression by effects that influence both initiation and progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/182\">",
"     182",
"    </a>",
"    ]. Some observational studies (cross sectional studies and especially long-term prospective studies) have revealed a link between poor vitamin D&nbsp;status and the risk of many cancers. An analysis by the World Health Organization (WHO) identified colon cancer as the type of cancer with the greatest risk associated with poor vitamin D status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/183\">",
"     183",
"    </a>",
"    ]. This finding was supported by a meta-analysis of nine case-control studies, which showed that each 4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    increase in pre-diagnosis serum 25OHD concentration was associated with a 6 percent decrease in colorectal cancer prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/184\">",
"     184",
"    </a>",
"    ]. It is not clear if these observed associations are causal as the current interventional data on the protective effect of vitamin D supplementation on the development of colorectal neoplasia are conflicting and additional studies are ongoing. This subject is addressed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=see_link&amp;anchor=H651662#H651662\">",
"     \"Vitamin D and extraskeletal health\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies suggest that dietary magnesium may influence colorectal cancer development. A population based study from Sweden found an inverse association between magnesium intake and the risk of colorectal cancer in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/185\">",
"     185",
"    </a>",
"    ]. Compared with women in the lowest quintile of magnesium intake, the risk was reduced by approximately 40 percent (RR 0.59, 95% CI 0.40-0.87) in women with the highest quintile of intake. The inverse association was observed for both colon and rectal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Garlic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of garlic has been associated with a reduced risk of colonic adenomas in some observational studies of patients with colorectal cancer and in laboratory studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/186,187\">",
"     186,187",
"    </a>",
"    ]. Garlic has been included as a probable protective factor by the World Cancer Research",
"    <span class=\"nowrap\">",
"     Fund/American",
"    </span>",
"    Institute of Cancer Research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/187\">",
"     187",
"    </a>",
"    ] but a review by the US Food and Drug Administration concluded that there as &ldquo;very limited credible evidence for a relation between garlic consumption and reduced colon cancer risk&rdquo;. Additional prospective intervention studies are needed to settle this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fish consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of omega 3 fatty acids (mainly as fish oil) has been associated with a reduced incidence of colorectal cancer in observational studies. A meta-analysis of 22 prospective cohort and 19 case-control studies found an overall lower incidence of colorectal cancer among individuals with the highest compared with the lowest fish consumption (summary odds ratio [OR] 0.88, 95% CI 0.80-0.95 ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/188\">",
"     188",
"    </a>",
"    ]. Thus, the association appears to be modest and intervention trials have not yet been reported. Two grams daily of Eicosopentaenoic Acid (EPA) as its free fatty acid has been shown in a randomized controlled trial to reduce the numbers of adenomas by a net change of 22.4 percent compared with placebo, as well as to improve the global polyp burden, in familial adenomatous polyposis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/189\">",
"     189",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently there are no generally accepted chemopreventive recommendations for patients at average risk for CRC but several agents have been shown to have modest to moderate chemopreventive effects in average and high risk populations.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Aspirin and NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial body of observational and intervention trial evidence suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs (NSAIDs) protect against the development of colonic adenomas and cancer. Regular use of aspirin and other NSAIDs are associated with a 20 to 40 percent reduction in the risk of colonic adenomas and colorectal cancer in individuals at average risk. Late follow up reports of the British randomized controlled trials of aspirin primarily addressing cardiovascular endpoints are now reporting similar reductions of 50 percent in colorectal and other cancer incidences and death, after a delayed (latent) period of at least five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/190,191\">",
"     190,191",
"    </a>",
"    ]. Low and high doses of aspirin were protective, and the effect was more marked for adenocarcinomas especially where proximal and with longer durations of aspirin use within the RCTs, The absolute reduction in fatal colorectal cancer was 1.76 percent (0.61-2.91; p=0.001). Definitive evidence for the protective effects of aspirin at 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in Lynch syndrome has emerged from the CAPP2 trial, evidence which will likely be written into guidelines worldwide. With a mean of 55.7 months follow up, Poisson regression taking into account multiple primary events (as is common in Lynch syndrome) gave an incidence ratio of 0.6 (95% CI 0.32-0.99; p=0.05) with a per protocol analysis of incidence ratio of 0.37 (95% CI 0.18-0.78; p=0.008) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/192\">",
"     192",
"    </a>",
"    ]. How long-term aspirin or NSAID therapy might protect against CRC is not well understood. Proposed explanations are increased apoptosis and impairment of tumor cell growth by inhibition of cyclooxygenase-2. The minimum dose of aspirin to achieve the protective effect is still uncertain and will be the objective of a new CAPP trial in Lynch Syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/193\">",
"     193",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/17/44312?source=see_link\">",
"     Sulindac",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    have been shown to cause regression of adenomas in familial adenomatous polyposis (FAP), and celecoxib was approved for a time as an adjunct to surgery for the treatment of this condition.",
"   </p>",
"   <p>",
"    These data are presented in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265276870\">",
"    <span class=\"h3\">",
"     DFMO plus sulindac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprevention with the combination of difluoromethylornithine (DFMO) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    (a nonsteroidal antiinflammatory drug) was evaluated in a randomized controlled trial involving 375 patients with a history of a resected colonic adenoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/194\">",
"     194",
"    </a>",
"    ]. DFMO is an enzyme-activated irreversible inhibitor of ornithine decarboxylase, the first enzyme in polyamine synthesis. It was initially developed as a chemotherapy agent because of its cytostatic effects on a variety of cell lines.",
"   </p>",
"   <p>",
"    The patients were randomly assigned to combination therapy or placebo for three years. The trial was halted after an interim analysis found marked significant reductions in the rate of recurrent adenomas (12 versus 41 percent, risk ratio 0.30), advanced adenomas (0.7 versus 8.5 percent, risk ratio 0.09), and multiple adenomas (0.7 versus 13.2 percent, risk ratio 0.06). Active therapy was associated with a higher rate of mild, subclinical changes in the audiogram (18.4 versus 9.8 percent), which improved in some patients after drug discontinuation.",
"   </p>",
"   <p>",
"    Large trials evaluating the efficacy and safety of this regimen have been proposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal hormone therapy (both combined estrogen plus progestin and unopposed estrogen) has been linked to a reduced risk of colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/195-203\">",
"     195-203",
"    </a>",
"    ]. As an example, a reduction in colorectal cancer risk was noted in the Women's Health Initiative (WHI) in women taking combined estrogen plus progestin hormone therapy (hazard ratio [HR] 0.56) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/204\">",
"     204",
"    </a>",
"    ]. This protective effect remained even after women who reported having screening sigmoidoscopy were excluded. No significant difference in the risk of colorectal cancer compared to placebo (HR 1.08) was noted in the unopposed conjugated equine estrogen arm in the WHI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/195\">",
"     195",
"    </a>",
"    ]. An important finding was that although women receiving combined estrogen and progestin had a lower diagnosis rate of CRC than did the control group, the tumors that did occur in this group were found at a more advanced stage than those found in the control group.",
"   </p>",
"   <p>",
"    Longer term follow up of the WHI data confirmed that the CRCs diagnosed in women receiving combined hormonal therapy were more advanced at diagnosis (regional or distant metastases in 69 versus 51 percent), and were associated with a non-statistically significant",
"    <strong>",
"     <em>",
"      higher",
"     </em>",
"    </strong>",
"    mortality rate (37 versus 27 deaths, 0.04 versus 0.03 percent, HR for death 1.29, 95% CI 0.78-2.11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/205\">",
"     205",
"    </a>",
"    ]. These data suggest the puzzling possibility that HRT may decrease CRC incidence but not mortality. Such a paradox could be explained by a systematic diagnostic delay in women receiving combined estrogen and progestin postmenopausal hormone therapy or could suggest that HRT actually affects the biology of CRC.",
"   </p>",
"   <p>",
"    Even before the most recent data cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/205\">",
"     205",
"    </a>",
"    ], postmenopausal hormone therapy was not recommended for chemoprevention of colon cancer in women because of the associated long-term risks of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link&amp;anchor=H9#H9\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Colorectal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some observational data suggest that statins are associated with a protective effect against several cancers, including colon cancer, but overall, the data are conflicting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=see_link&amp;anchor=H3#H3\">",
"     \"Statins: Possible noncardiovascular benefits\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data regarding CRC are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A modest reduction in the incidence of colon cancer, as a secondary endpoint, was observed in two large clinical trials evaluating the benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      for coronary artery disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/206,207\">",
"       206,207",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reduced risk of CRC was also observed in the Molecular Epidemiology of Colorectal Cancer (MECC) study, a population-based case-control study in which data regarding personal and family history of cancer, medical conditions, medication use, physical activity, and nutrition were collected from 1953 patients diagnosed with CRC and 2015 population-based controls matched for age, gender and ethnicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/208\">",
"       208",
"      </a>",
"      ]. In this study, use of statins for at least five years was associated with a significant reduction in the risk of CRC (odds ratio [OR] 0.53, 95% CI 0.38-0.74) after adjustment for use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other NSAIDs, physical activity, hypercholesterolemia, vegetable consumption, and family history. A potential confounding factor is that the cancer population and the controls were drawn from two different databases.",
"     </li>",
"     <li>",
"      Other case-control studies have failed to document a protective benefit of statin use against colon cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/209-212\">",
"       209-212",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The explanation for these conflicting results is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several interventional trials have evaluated the efficacy of antioxidants in the prevention of colorectal adenomas. A meta-analysis of eight controlled trials found no convincing evidence that antioxidant supplements had a significant beneficial effect on primary or secondary prevention of colorectal adenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/213\">",
"     213",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21344519\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral bisphosphonates are commonly used for the treatment of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data linking bisphosphonate use with protection from colorectal cancer are conflicting. The possibility that long-term bisphosphonate use was associated with a reduced risk of colorectal cancer was initially suggested in two case-control studies and one cohort study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/214-216\">",
"     214-216",
"    </a>",
"    ], but not confirmed in a third case-control study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/217\">",
"     217",
"    </a>",
"    ] or a large prospective cohort study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/218\">",
"     218",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based case control study, use of oral bisphosphonates for more than one year was associated with a significant reduction in the risk of CRC (RR 0.50, 95% CI 0.35 to 0.71) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/214\">",
"       214",
"      </a>",
"      ]. The association persisted after adjustment for vegetable intake, physical activity, family history of CRC, body mass index, and use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , statins, vitamin D, and postmenopausal hormone therapy (RR 0.41, 95% CI 0.25 to 0.67).",
"      <br/>",
"      <br/>",
"      A similar inverse relationship between bisphosphonate use and risk of CRC was shown in a second retrospective study, although of a lesser magnitude (odds ratio [OR] for &ge;14 bisphosphonate prescriptions over &ge;5 years 0.78; 95% CI, 0.65-0.94) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/215\">",
"       215",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of three case-control studies with a total of 16,998 CRC cases and 108,197 controls, and one cohort study with 94,405 individuals exposed to bisphosphonates and 283,181 unexposed to bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/214-217\">",
"     214-217",
"    </a>",
"    ] suggested a marginally reduced risk of CRC with any exposure to oral bisphosphonates (odds ratio [OR] 0.71, 95% CI 0.78-0.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/219\">",
"     219",
"    </a>",
"    ]. The inverse relationship was statistically significant at a dose of 10 or more prescriptions, or one or more years of oral bisphosphonate use.",
"   </p>",
"   <p>",
"    For unclear reasons, the analysis did not include a second null study of a cohort of 86,277 women enrolled onto the Nurses&rsquo; Health Study, 801 of whom developed colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/25/42394/abstract/218\">",
"     218",
"    </a>",
"    ]. The age-adjusted hazard ratio [HR] for colorectal cancer among women who regularly used bisphosphonates was 0.92 (95% CI 0.73-1.14) and was further attenuated after adjustment for other risk factors (HR 1.14, 95% CI 0.82-1.33). Risk was not influenced by duration of therapy. &nbsp;",
"   </p>",
"   <p>",
"    Given the inconsistency of the data, and the apparent lack of a dose response, the issue of whether use of oral bisphosphonates protects against CRC remains unsettled. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7541?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major factors that increase the risk of colon cancer include hereditary forms of colorectal cancer, age, a personal or family history of sporadic colorectal cancer (and possibly large or advanced adenomas), and inflammatory bowel disease. Several potentially modifiable risk factors including obesity and lack of physical activity have been consistently identified in observational studies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A substantial body of evidence supports a protective effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other nonsteroidal antiinflammatory drugs on the development of colonic adenomas and cancer. Aspirin can be considered in selected patients with Lynch syndrome for chemoprevention of Lynch syndrome-associated cancers. The potential role of aspirin and other NSAIDs in colorectal cancer prevention is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=see_link\">",
"       \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other protective factors have also been identified mainly in observational studies, but the strength of these associations is uncertain. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Protective factors'",
"      </a>",
"      above.) Nevertheless, a protective diet can be defined for clinical purposes to include avoidance of processed and charred red meat, inclusion of vegetables (especially cruciferous), and unprocessed forms of wheat bran (controversial), an adequate amount of intake of folate from food, limited caloric intake, and avoidance of excessive alcohol.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/2\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/4\">",
"      Doubeni CA, Laiyemo AO, Major JM, et al. Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer 2012; 118:3636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/5\">",
"      Willett WC. Diet and cancer: an evolving picture. JAMA 2005; 293:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/6\">",
"      Doubeni CA, Major JM, Laiyemo AO, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst 2012; 104:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/7\">",
"      Klabunde CN, Cronin KA, Breen N, et al. Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev 2011; 20:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/8\">",
"      Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/9\">",
"      Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/10\">",
"      Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990; 113:373.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cancervic.org.au/downloads/cec/cancer-in-vic/CCV-Statistics-trends.pdf (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/12\">",
"      Davis DM, Marcet JE, Frattini JC, et al. Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg 2011; 213:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/13\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/14\">",
"      Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975-1994. Cancer 1999; 85:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/15\">",
"      Jessup JM, McGinnis LS, Steele GD Jr, et al. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/16\">",
"      Th&ouml;rn M, Bergstr&ouml;m R, Kressner U, et al. Trends in colorectal cancer incidence in Sweden 1959-93 by gender, localization, time period, and birth cohort. Cancer Causes Control 1998; 9:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/17\">",
"      Stewart RJ, Stewart AW, Turnbull PR, Isbister WH. Sex differences in subsite incidence of large-bowel cancer. Dis Colon Rectum 1983; 26:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/18\">",
"      Mamazza J, Gordon PH. The changing distribution of large intestinal cancer. Dis Colon Rectum 1982; 25:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/19\">",
"      Vukasin AP, Ballantyne GH, Flannery JT, et al. Increasing incidence of cecal and sigmoid carcinoma. Data from the Connecticut Tumor Registry. Cancer 1990; 66:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/20\">",
"      Schub R, Steinheber FU. Rightward shift of colon cancer. A feature of the aging gut. J Clin Gastroenterol 1986; 8:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/21\">",
"      Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59:366.",
"     </a>",
"    </li>",
"    <li>",
"     Ries L, Kosary CL, Hankey BF, et al. SEER cancer statistics review 1973-1995. National Cancer Institute, Bethesda, MD 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/23\">",
"      Wei EK, Giovannucci E, Wu K, et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer 2004; 108:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/24\">",
"      Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 138:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/25\">",
"      Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 1995; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/26\">",
"      Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993; 104:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/27\">",
"      Ponz de Leon M, Sassatelli R, Benatti P, Roncucci L. Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry. Cancer 1993; 71:3493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/28\">",
"      Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993; 75:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/29\">",
"      Locker GY, Lynch HT. Genetic factors and colorectal cancer in Ashkenazi Jews. Fam Cancer 2004; 3:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/30\">",
"      Chan TL, Yuen ST, Kong CK, et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006; 38:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/31\">",
"      Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011; 12:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/32\">",
"      Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/33\">",
"      Jenkins MA, Baglietto L, Dowty JG, et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 2006; 4:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/34\">",
"      Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/35\">",
"      Winawer SJ, Zauber AG, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/36\">",
"      Ahsan H, Neugut AI, Garbowski GC, et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/37\">",
"      Cottet V, Pariente A, Nalet B, et al. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology 2007; 133:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/38\">",
"      Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. Ann Intern Med 2012; 156:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/39\">",
"      Madlensky L, Daftary D, Burnett T, et al. Accuracy of colorectal polyp self-reports: findings from the colon cancer family registry. Cancer Epidemiol Biomarkers Prev 2007; 16:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/40\">",
"      Nakama H, Zhang B, Fukazawa K, Abdul Fattah AS. Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer. Eur J Cancer 2000; 36:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/41\">",
"      Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/42\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     National Guideline Clearinghouse. Practice guidelines: colorectal cancer screening. Paris: World Gastroenterology Organisation; 2007. www.guideline.gov/content.aspx?id=12143 (Accessed on May 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/44\">",
"      Colorectal cancer screening. Recommendation statement from the Canadian task force on preventive health care. Can Fam Physician 2001; 47:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/45\">",
"      Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/46\">",
"      Henderson TO, Oeffinger KC, Whitton J, et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 2012; 156:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/47\">",
"      Nottage K, McFarlane J, Krasin MJ, et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol 2012; 30:2552.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.survivorshipguidelines.org/pdf/ColorectalCancer.pdf (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/49\">",
"      Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 2005; 128:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/50\">",
"      Cash BD, Banerjee S, Anderson MA, et al. Ethnic issues in endoscopy. Gastrointest Endosc 2010; 71:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/51\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/52\">",
"      U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/53\">",
"      Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/54\">",
"      Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 2009; 70:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/55\">",
"      Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80:3223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/56\">",
"      Fukuda I, Hizuka N, Murakami Y, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 2001; 40:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/57\">",
"      Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/58\">",
"      Park JM, Choi MG, Kim SW, et al. Increased incidence of colorectal malignancies in renal transplant recipients: a case control study. Am J Transplant 2010; 10:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/59\">",
"      Webster AC, Craig JC, Simpson JM, et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007; 7:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/60\">",
"      Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/61\">",
"      Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999; 91:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/62\">",
"      Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/63\">",
"      Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/64\">",
"      Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/65\">",
"      He J, Stram DO, Kolonel LN, et al. The association of diabetes with colorectal cancer risk: the Multiethnic Cohort. Br J Cancer 2010; 103:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/66\">",
"      Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/67\">",
"      Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 2011; 106:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/68\">",
"      Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 2012; 57:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/69\">",
"      Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/70\">",
"      Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 1989; 80:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/71\">",
"      Watkins LF, Lewis LR, Levine AE. Characterization of the synergistic effect of insulin and transferrin and the regulation of their receptors on a human colon carcinoma cell line. Int J Cancer 1990; 45:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/72\">",
"      Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/73\">",
"      Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004; 96:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/74\">",
"      Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/75\">",
"      Campbell PT, Deka A, Jacobs EJ, et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 2010; 139:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/76\">",
"      Dehal AN, Newton CC, Jacobs EJ, et al. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012; 30:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/77\">",
"      Gillessen S, Templeton A, Marra G, et al. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst 2010; 102:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/78\">",
"      Lin JH, Giovannucci E. Sex hormones and colorectal cancer: what have we learned so far? J Natl Cancer Inst 2010; 102:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/79\">",
"      Lagergren J, Ye W, Ekbom A. Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? Gastroenterology 2001; 121:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/80\">",
"      Giovannucci E, Colditz GA, Stampfer MJ. A meta-analysis of cholecystectomy and risk of colorectal cancer. Gastroenterology 1993; 105:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/81\">",
"      Reid FD, Mercer PM, harrison M, Bates T. Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis. Scand J Gastroenterol 1996; 31:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/82\">",
"      Todoroki I, Friedman GD, Slattery ML, et al. Cholecystectomy and the risk of colon cancer. Am J Gastroenterol 1999; 94:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/83\">",
"      Mercer PM, Reid FD, Harrison M, Bates T. The relationship between cholecystectomy, unoperated gallstone disease, and colorectal cancer. A necropsy study. Scand J Gastroenterol 1995; 30:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/84\">",
"      Berr F, Stellaard F, Pratschke E, Paumgartner G. Effects of cholecystectomy on the kinetics of primary and secondary bile acids. J Clin Invest 1989; 83:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/85\">",
"      Tocchi A, Basso L, Costa G, et al. Is there a causal connection between bile acids and colorectal cancer? Surg Today 1996; 26:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/86\">",
"      van der Linden W, Katzenstein B, Nakayama F. The possible carcinogenic effect of cholecystectomy. No postoperative increase in the proportion of secondary bile acids. Cancer 1983; 52:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/87\">",
"      Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol 2011; 22:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/88\">",
"      Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/89\">",
"      Mizoue T, Inoue M, Wakai K, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol 2008; 167:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/90\">",
"      Harnack L, Jacobs DR Jr, Nicodemus K, et al. Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of colorectal cancers. Nutr Cancer 2002; 43:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/91\">",
"      Giovannucci E, Rimm EB, Ascherio A, et al. Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 1995; 87:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/92\">",
"      Mart&iacute;nez ME, Giovannucci E, Spiegelman D, et al. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst 1997; 89:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/93\">",
"      Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995; 122:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/94\">",
"      Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/95\">",
"      Chan AO, Jim MH, Lam KF, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007; 298:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/96\">",
"      Botteri E, Iodice S, Bagnardi V, et al. Smoking and colorectal cancer: a meta-analysis. JAMA 2008; 300:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/97\">",
"      Botteri E, Iodice S, Raimondi S, et al. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 2008; 134:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/98\">",
"      Wallace K, Grau MV, Ahnen D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev 2009; 18:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/99\">",
"      Buchanan DD, Sweet K, Drini M, et al. Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. PLoS One 2010; 5:e11636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/100\">",
"      Pande M, Lynch PM, Hopper JL, et al. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. Clin Cancer Res 2010; 16:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/101\">",
"      Stewart M, Macrae FA, Williams CB. Neoplasia and ureterosigmoidostomy: a colonoscopy survey. Br J Surg 1982; 69:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/102\">",
"      Chao A, Thun MJ, Connell CJ, et al. Meat consumption and risk of colorectal cancer. JAMA 2005; 293:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/103\">",
"      Norat T, Bingham S, Ferrari P, et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 2005; 97:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/104\">",
"      Willett WC, Stampfer MJ, Colditz GA, et al. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 1990; 323:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/105\">",
"      Cross AJ, Ferrucci LM, Risch A, et al. A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. Cancer Res 2010; 70:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/106\">",
"      Chan DS, Lau R, Aune D, et al. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. PLoS One 2011; 6:e20456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/107\">",
"      MacLennan R, Macrae F, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst 1995; 87:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/108\">",
"      Giovannucci E. Meta-analysis of coffee consumption and risk of colorectal cancer. Am J Epidemiol 1998; 147:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/109\">",
"      Sinha R, Cross AJ, Daniel CR, et al. Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study. Am J Clin Nutr 2012; 96:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/110\">",
"      Michels KB, Willett WC, Fuchs CS, Giovannucci E. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst 2005; 97:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/111\">",
"      Zhang X, Albanes D, Beeson WL, et al. Risk of colon cancer and coffee, tea, and sugar-sweetened soft drink intake: pooled analysis of prospective cohort studies. J Natl Cancer Inst 2010; 102:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/112\">",
"      Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/113\">",
"      Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/114\">",
"      Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/115\">",
"      Niell BL, Rennert G, Bonner JD, et al. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 2004; 96:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/116\">",
"      Kirchhoff T, Satagopan JM, Kauff ND, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 2004; 96:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/117\">",
"      Siersema PD, Yu S, Sahbaie P, et al. Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc 2006; 63:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/118\">",
"      Vaughan TL, Kiemeney LA, McKnight B. Colorectal cancer in patients with esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 1995; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/119\">",
"      Cauvin JM, Goldfain D, Le Rhun M, et al. Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett. Lancet 1995; 346:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/120\">",
"      Laitakari R, Laippala P, Isolauri J. Barrett's oesophagus is not a risk factor for colonic neoplasia: a case-control study. Ann Med 1995; 27:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/121\">",
"      Lagergren J, Nyren O. No association between colon cancer and adenocarcinoma of the oesophagus in a population based cohort study in Sweden. Gut 1999; 44:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/122\">",
"      Schouten LJ, Steevens J, Huysentruyt CJ, et al. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2011; 9:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/123\">",
"      Andrici J, Tio M, Cox MR, Eslick GD. Meta-analysis: Barrett's oesophagus and the risk of colonic tumours. Aliment Pharmacol Ther 2013; 37:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/124\">",
"      Burnett-Hartman AN, Newcomb PA, Potter JD. Infectious agents and colorectal cancer: a review of Helicobacter pylori, Streptococcus bovis, JC virus, and human papillomavirus. Cancer Epidemiol Biomarkers Prev 2008; 17:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/125\">",
"      Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/126\">",
"      Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/127\">",
"      Zhang Y, Hoffmeister M, Weck MN, et al. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol 2012; 175:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/128\">",
"      Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 2011; 53:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/129\">",
"      Bini EJ, Park J, Francois F. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006; 166:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/130\">",
"      Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/131\">",
"      J&auml;nne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/132\">",
"      Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009; 100:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/133\">",
"      Boyle T, Keegel T, Bull F, et al. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/134\">",
"      Kim YI, Mason JB. Nutrition chemoprevention of gastrointestinal cancers: a critical review. Nutr Rev 1996; 54:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/135\">",
"      Terry P, Giovannucci E, Michels KB, et al. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst 2001; 93:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/136\">",
"      Slattery ML, Boucher KM, Caan BJ, et al. Eating patterns and risk of colon cancer. Am J Epidemiol 1998; 148:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/137\">",
"      Michels KB, Joshipura KJ, Rosner BA, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000; 92:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/138\">",
"      Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 2007; 99:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/139\">",
"      Lee JE, Chan AT. Fruit, vegetables, and folate: cultivating the evidence for cancer prevention. Gastroenterology 2011; 141:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/140\">",
"      J&auml;rvinen R, Knekt P, Hakulinen T, et al. Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer 2001; 85:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/141\">",
"      Butler LM, Sinha R, Millikan RC, et al. Heterocyclic amines, meat intake, and association with colon cancer in a population-based study. Am J Epidemiol 2003; 157:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/142\">",
"      Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002; 31:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/143\">",
"      Negri E, Franceschi S, Parpinel M, La Vecchia C. Fiber intake and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/144\">",
"      Peters U, Sinha R, Chatterjee N, et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 2003; 361:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/145\">",
"      Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/146\">",
"      Larsson SC, Giovannucci E, Bergkvist L, Wolk A. Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60,000 women. Br J Cancer 2005; 92:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/147\">",
"      Dahm CC, Keogh RH, Spencer EA, et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst 2010; 102:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/148\">",
"      Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 1999; 340:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/149\">",
"      Beresford SA, Johnson KC, Ritenbaugh C, et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/150\">",
"      Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005; 294:2849.",
"     </a>",
"    </li>",
"    <li>",
"     World Cancer Research Fund and American Institute for Cancer Research. Colorectal cancer report 2010: Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. file://www.wcrf.org/PDFs/Colorectal%20cancer%20report%20summary%202011.pdf (Accessed on September 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/152\">",
"      Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 2011; 343:d6617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/153\">",
"      Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000; 342:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/154\">",
"      Alberts DS, Mart&iacute;nez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000; 342:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/155\">",
"      Asano T, McLeod RS. Dietary fibre for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2002; :CD003430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/156\">",
"      Ferguson LR, Harris PJ. The dietary fibre debate: more food for thought. Lancet 2003; 361:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/157\">",
"      American Gastroenterological Association medical position statement: impact of dietary fiber on colon cancer occurrence. American College of Gastroenterology. Gastroenterology 2000; 118:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/158\">",
"      Williams EA, Coxhead JM, Mathers JC. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc Nutr Soc 2003; 62:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/159\">",
"      Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/160\">",
"      Mathers JC, Movahedi M, Macrae F, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol 2012; 13:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/161\">",
"      Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2000; 130:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/162\">",
"      Lee JE, Willett WC, Fuchs CS, et al. Folate intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin Nutr 2011; 93:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/163\">",
"      Sanjoaquin MA, Allen N, Couto E, et al. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 2005; 113:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/164\">",
"      Ulvik A, Evensen ET, Lien EA, et al. Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am J Med Genet 2001; 101:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/165\">",
"      Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/166\">",
"      Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/167\">",
"      Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 2007; 16:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/168\">",
"      Stevens VL, McCullough ML, Sun J, et al. High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. Gastroenterology 2011; 141:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/169\">",
"      Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA 2010; 303:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/170\">",
"      Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2004; :CD003548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/171\">",
"      Holt PR, Atillasoy EO, Gilman J, et al. Modulation of abnormal colonic epithelial cell proliferation and differentiation by low-fat dairy foods: a randomized controlled trial. JAMA 1998; 280:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/172\">",
"      Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999; 340:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/173\">",
"      Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000; 95:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/174\">",
"      Wu K, Willett WC, Fuchs CS, et al. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 2002; 94:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/175\">",
"      Kim HS, Newcomb PA, Ulrich CM, et al. Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomarkers Prev 2001; 10:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/176\">",
"      Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 2004; 96:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/177\">",
"      Park Y, Leitzmann MF, Subar AF, et al. Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study. Arch Intern Med 2009; 169:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/178\">",
"      Shaukat A, Scouras N, Sch&uuml;nemann HJ. Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol 2005; 100:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/179\">",
"      Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/180\">",
"      Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003; 95:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/181\">",
"      Aune D, Lau R, Chan DS, et al. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. Ann Oncol 2012; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/182\">",
"      Byers SW, Rowlands T, Beildeck M, Bong YS. Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev Endocr Metab Disord 2012; 13:31.",
"     </a>",
"    </li>",
"    <li>",
"     IARC. Vitamin D and Cancer. IARC Working Group Reports Vol.5, International Agency for research on Cancer, Lyon. November 2008. file://www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/Report_VitD.pdf .",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/184\">",
"      Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/185\">",
"      Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. JAMA 2005; 293:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/186\">",
"      Ngo SN, Williams DB, Cobiac L, Head RJ. Does garlic reduce risk of colorectal cancer? A systematic review. J Nutr 2007; 137:2264.",
"     </a>",
"    </li>",
"    <li>",
"     World Cancer Research Fund/American Institute of Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective, AICR, Washington DC 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/188\">",
"      Wu S, Feng B, Li K, et al. Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. Am J Med 2012; 125:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/189\">",
"      West NJ, Clark SK, Phillips RK, et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010; 59:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/190\">",
"      Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/191\">",
"      Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/192\">",
"      Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378:2081.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trial information available at www.CAPP3.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/194\">",
"      Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008; 1:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/195\">",
"      Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/196\">",
"      Johnson JR, Lacey JV Jr, Lazovich D, et al. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/197\">",
"      Rennert G, Rennert HS, Pinchev M, et al. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol 2009; 27:4542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/198\">",
"      Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/199\">",
"      Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998; 128:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/200\">",
"      Fernandez E, La Vecchia C, Braga C, et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/201\">",
"      Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/202\">",
"      Green J, Czanner G, Reeves G, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 2012; 130:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/203\">",
"      Lin KJ, Cheung WY, Lai JY, Giovannucci EL. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 2012; 130:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/204\">",
"      Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/205\">",
"      Simon MS, Chlebowski RT, Wactawski-Wende J, et al. Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol 2012; 30:3983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/206\">",
"      Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/207\">",
"      Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/208\">",
"      Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/209\">",
"      Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90:635.",
"     </a>",
"    </li>",
"    <li>",
"     Khurana V, Singh T, Chalasani R, et al. Statins do not reduce colon cancer risk in humans: a case control study. Gastroenterology 2004; 126(Suppl):A452.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/211\">",
"      Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007; 99:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/212\">",
"      Singh H, Mahmud SM, Turner D, et al. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009; 104:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/213\">",
"      Bjelakovic G, Nagorni A, Nikolova D, et al. Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma. Aliment Pharmacol Ther 2006; 24:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/214\">",
"      Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011; 29:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/215\">",
"      Singh H, Nugent Z, Demers A, et al. Exposure to bisphosphonates and risk of colorectal cancer: a population-based nested case-control study. Cancer 2012; 118:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/216\">",
"      Vestergaard P. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 2011; 89:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/217\">",
"      Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341:c4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/218\">",
"      Khalili H, Huang ES, Ogino S, et al. A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol 2012; 30:3229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/25/42394/abstract/219\">",
"      Thosani N, Thosani SN, Kumar S, et al. Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol 2013; 31:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2606 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42394=[""].join("\n");
var outline_f41_25_42394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90629946\">",
"      Factors that currently influence screening recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90629953\">",
"      - Hereditary CRC syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H281689727\">",
"      MUTYH-associated polyposis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lynch syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Personal or family history of sporadic CRCs or adenomatous polyps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16092481\">",
"      Ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16092488\">",
"      Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15837087\">",
"      - Abdominal radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265276647\">",
"      Factors that may influence screening recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90630106\">",
"      - Race/ethnicity and gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265276695\">",
"      - Acromegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265276753\">",
"      - Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90630250\">",
"      Risk factors that do not alter screening recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diabetes mellitus and insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19181667\">",
"      - Use of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROTECTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90630437\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fiber",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Resistant starch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Folic acid and folate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Vitamin B6 (pyridoxine)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Calcium and dairy products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4999625\">",
"      - Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Magnesium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Garlic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fish consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Aspirin and NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265276870\">",
"      - DFMO plus sulindac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21344519\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2606|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/60/10191\" title=\"diagnostic image 1\">",
"      Sigmoid cancer in UC BE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2606|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/17/37151\" title=\"figure 1\">",
"      Incidence of CRC with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2606|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/19/8504\" title=\"picture 1\">",
"      Familial polyposis Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/12/30917\" title=\"picture 2\">",
"      Familial polyposis Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2606|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/8/23693\" title=\"table 1\">",
"      Scrn CRC MSTF recs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22041?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40342?source=related_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/15/38137?source=related_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6041?source=related_link\">",
"      Pretreatment local staging evaluation for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=related_link\">",
"      Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/34/32298?source=related_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_25_42395="ASCO recommend lung CA followup";
var content_f41_25_42395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2004 ASCO* recommendations for lung cancer follow-up care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Guideline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History and physical examination",
"       </td>",
"       <td>",
"        For",
"patients treated with curative intent, in the absence of symptoms, a",
"history and physical exam should be performed every 3 months during the",
"first 2 years; every 6 months thereafter through year 5, and yearly thereafter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest radiographs",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        For patients treated with curative",
"intent, there is no clear role for routine chest x-rays in asymptomatic",
"patients and for those in whom no intervention is planned.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complete blood cell count",
"       </td>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Only performed as indicated by the patient's symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        CT scans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        Automated chemistry studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        Bone scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        Bronchoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        CT/MRI of the brain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        PET scan",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * ASCO: American Society of Clinical Oncology.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Pfister, DG, et al. J Clin Oncol 2004; 22:330.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42395=[""].join("\n");
var outline_f41_25_42395=null;
var title_f41_25_42396="Body position and airway size";
var content_f41_25_42396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of body position on airway size",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oropharyngeal area in the seated and supine positions during wakefulness. The airway size falls in the supine position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Martin SE, Marshall I, Douglas NJ, Am J Respir Crit Care Med 1995; 152:721.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42396=[""].join("\n");
var outline_f41_25_42396=null;
var title_f41_25_42397="Buddy taping";
var content_f41_25_42397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Buddy taping of the toes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 180px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fractured toe is secured to the adjacent toe with adhesive strips. Sheet wadding between the toes helps to prevent maceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42397=[""].join("\n");
var outline_f41_25_42397=null;
var title_f41_25_42398="Serology acute and chronic HBV";
var content_f41_25_42398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 585px\">",
"   <div class=\"ttl\">",
"    Serologic responses to HBV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 565px; height: 208px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the serologic responses to acute and chronic hepatitis B virus (HBV) infection in relation to the serum alanine aminotransferase (ALT) concentration. Left panel: Acute infection is characterized initially by the presence of HBeAg (hepatitis B e antigen), HBsAg (hepatitis B surface antigen), and HBV DNA beginning in the preclinical phase. IgM anti-HBc (hepatitis B core antigen) appears early in the clinical phase; the combination of this antibody and HBsAg makes the diagnosis of acute infection. Recovery is accompanied by normalization of the serum ALT, the disappearance of HBV DNA, HBeAg to anti-HBe seroconversion, and subsequently HBsAg to anti-HBs seroconversion and switch from IgM to IgG anti-HBc. Thus, previous HBV infection is characterized by anti-HBs and IgG anti-HBc. Right panel: Chronic infection is characterized by persistence of HBeAg (for a variable period), HBsAg, and HBV DNA in the circulation; anti-HBs is not seen (in approximately 20 percent of patients a non-neutralizing form of anti-HBs can be detected). Persistence of HBsAg for more than six months after acute infection is considered indicative of chronic infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42398=[""].join("\n");
var outline_f41_25_42398=null;
var title_f41_25_42399="Autoeczematous reaction";
var content_f41_25_42399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoeczematous reaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several areas of autoeczematization on the leg and thigh of a patient with venous insufficiency and stasis dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_25_42399=[""].join("\n");
var outline_f41_25_42399=null;
